Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
Division of HIV/AIDS Prevention

External Peer Review of DHAP’s HIV Prevention Activities

Summary Report
Findings and Recommendations

November 1, 2009
# Table of Contents

I. Introduction..................................................................................................................................... 1  
   A. About this Report ............................................................................................................................ 1  
   B. Steering Committee ....................................................................................................................... 2  
   C. Planning, Prioritizing and Monitoring .......................................................................................... 3  
   D. Surveillance ...................................................................................................................................... 3  
II. Panel Summaries .......................................................................................................................... 2  
   A. DHAP Background ....................................................................................................................... 55  
   B. Biomedical Interventions, Diagnostics, Laboratory, and Health Services Research .................. 5  
   C. Behavioral, Social, and Structural Interventions Research ......................................................... 5  
   D. Prevention Programs, Capacity Building, and Program Evaluation ........................................... 6  
III. Methods ......................................................................................................................................... 7  
   A. Review Process ............................................................................................................................ 7  
   B. Reviewer Selection Process .......................................................................................................... 8  
   C. Chair and Co-Chair Selection Process ......................................................................................... 9  
IV. Steering Committee ..................................................................................................................... 14  
   A. Topics Addressed ........................................................................................................................... 15  
   B. Proportion of Activities .............................................................................................................. 15  
   C. Appropriateness of Activities ...................................................................................................... 16  
   D. Resource Allocation .................................................................................................................... 16  
   E. Knowledge Translation and Dissemination ................................................................................ 17  
   F. Capacity and Resources ............................................................................................................. 18  
   G. Program Gaps ............................................................................................................................. 19  
   H. CDC Role ...................................................................................................................................... 19  
   I. United States Role ....................................................................................................................... 19  
V. Panel Summaries ........................................................................................................................... 22  
   A. Planning, Prioritizing, and Monitoring ....................................................................................... 22  
   B. Surveillance .................................................................................................................................... 28  
   C. Biomedical Interventions, Diagnostics, Laboratory, and Health Services Research .............. 39  
   D. Behavioral, Social, and Structural Interventions Research ...................................................... 43  
VI. Appendices ................................................................................................................................... 47  
   A. DHAP Background ....................................................................................................................... 55  
   B. Guiding Questions for Review Panels ........................................................................................ 63  
   C. External Peer Review Panel Members ....................................................................................... 67  

---

External Peer Review  
Findings and Recommendations  
November 1, 2009  
Page i
Dear Colleagues,

Starting in the fall of 2008, the Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention (DHAP) began the External Peer Review (EPR) process of DHAP’s domestic HIV prevention activities. This important review covered DHAP’s surveillance, research, and HIV prevention programs and included a planning phase, the selection of a panel of experts, development of questions to be addressed and exhaustive briefing materials, convening the panel of experts, and the development of the report contained herein.

The purpose of the peer review was to obtain external review and feedback on DHAP’s domestic HIV prevention programs, including research and non-research (i.e., public health practice). The specific goals of the peer review were to:

   a. Provide DHAP with objective input and guidance on its scientific and programmatic priorities and direction.
   b. Serve as a basis for CDC’s next HIV Prevention Strategic Plan.
   c. Provide a platform for the development of a National HIV Prevention Plan that incorporates stakeholder perspectives and needs.

This report contains the findings and recommendations of the EPR and materials that provide background to the reader on DHAP’s programs and activities that were reviewed by the expert panel. This review required substantial effort from the panel members and the Division’s Peer Review Planning Committee and particularly from the many DHAP staff members who worked hard to plan, develop, and carry out the steps leading to the External Peer Review.

We want to recognize the efforts of the panel members in providing their input and working for several months to finalize this report. This process will greatly assist CDC in meeting the scientific and programmatic needs of the HIV epidemic, which is vital to stopping the spread of HIV/AIDS in the United States.

Regards,

Edward Hook, III, MD
University of Alabama, Birmingham
Chair

Jesse Milan, Jr., JD
Altarum Institute
Chair
I. INTRODUCTION

In the Fall of 2008, the Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Division of HIV/AIDS Prevention (DHAP), began the External Peer Review (EPR) of DHAP’s HIV Prevention Activities. This review consisted of convening a group of seventy-three (73) experts from state and local government, national partner organizations, academia, community-based organizations and risk population stakeholders from various parts of the country with experience in HIV prevention and familiarity with DHAP’s intramural and extramural activities to examine DHAP’s HIV prevention activities. This Peer Review would provide input to CDC on the scientific validity and quality of its activities and the appropriateness of activities to the identified need in the area of HIV/AIDS prevention.

To help guide the review process, DHAP developed a series of questions seeking input that would prove useful to CDC in determining the scientific validity of its activities and in planning for the future. Jesse Milan, JD, and Edward Hook, M.D., led the External Peer Reviewers and chaired a Steering Committee composed of the Co-Chairs of five panels who developed a series of overarching findings and recommendations. Each of the panels reviewed information provided by CDC and developed findings and recommendations in each of their areas. The panels focused upon the following:

- Planning, Prioritizing, and Monitoring
- Surveillance
- Biomedical Interventions, Diagnostics, Laboratory, and Health Services Research
- Behavioral, Social, and Structural Interventions Research
- Prevention Programs, Capacity Building, and Program Evaluation

A meeting of the EPR Reviewers and the various Panels and Steering Committee was held at the W Hotel Buckhead in Atlanta, Georgia on April 13–15, 2009. The meeting consisted of plenary presentations, panel discussions, Steering Committee discussions and a report-back session, where the Co-Chairs of the various panels reported to the entire group of EPR Reviewers and to CDC the most salient points of the discussion in their Panel.

A. ABOUT THIS REPORT

This report contains a summary of the findings and recommendations of the EPR Process, which is described in the Methods section. The Summary contains the most salient points from the Steering Committee and individual panels, which are followed by a description of the methods used to carry out this process, and greater detail on the findings and recommendations of the various panels. The findings and recommendations included here are those of the EPR members and Steering Committee without input from CDC staff. DHAP has been presented this report and has had an opportunity to draft a detailed response.
II. PANEL SUMMARIES

A. STEERING COMMITTEE

Led by the External Peer Review Chairs and comprised of all the Panel Co-chairs, the Steering Committee was charged with taking a macro-level view of DHAP’s efforts and approach. In response to this charge, the Steering Committee members were unanimous in their recognition of the important role of CDC in leading the nation’s domestic HIV prevention efforts and DHAP’s ability to work with constituents at the national, state and local levels. While these were seen as important roles, the Steering Committee saw opportunities for further growth, for improved prioritization of efforts, and for enhanced leadership on the part of CDC. The Steering Committee saw also a unique, central role for CDC in helping to guide the expected development of a federally created national plan for HIV in the United States and in bringing HIV prevention issues to our national debate on health care reform. Most importantly, the Steering Committee believed that its review would be especially useful at this juncture in CDC history with the arrival in July 2009 of the new DHAP Director.

The Steering Committee expressed a strong concern that DHAP should have been engaging in a more strategic variety of activities to better serve current needs and anticipated future trends without duplicating the efforts of other federal government agencies and nongovernmental partners. The Steering Committee expressed reservations on the process through which Division and Branch priorities were set as well as how scientific data from surveillance, behavioral and biomedical research, and program evaluation translated into program and research priorities. The Steering Committee also questioned whether current priorities were the most appropriate for the existing and future contributions of CDC to the HIV prevention needs of the United States.

Members of the Steering Committee recommended greater transparency from DHAP in priority-setting and decision-making processes and greater leadership in articulating the mix of activities needed to achieve HIV prevention goals across the United States. They urged CDC officials to resist CDC-internal and external cultural and ideological factors that may have impacted what activities and programs were carried out in the past. A stronger commitment must be made to embrace and pursue scientific validity and to document specifically how DHAP activities meet existing needs and accord with the current state of science. The organizational culture and structure of CDC were seen as barriers to more collaboration within DHAP, among Divisions within the Center, among federal and non-federal agencies, and to the speedy translation of knowledge into practice.

In regard to the current mix of activities, the Steering Committee urged greater rigor from DHAP to articulate combination approaches appropriate for various stages and concentrations of the epidemic across the United States with attention to the socio-economic conditions of affected communities and the technical capacity of local public health and community-based stakeholders to carry out needed interventions. Recognizing that external factors, funding or political considerations often affect which activities can be carried out, the Steering Committee recommended an increase in public awareness about HIV prevention sciences and other activities that heighten understanding of and demand for effective HIV prevention approaches in the United States.
In regards to future planning activities, the Steering Committee recommended that CDC accelerate the availability of data characterizing the epidemic, increase utilization of available data in planning, prioritize surveillance activities for support, and make data derived thereof more widely available in a more expeditious way to support planning nationally and at the state and local levels. The Panel also recommended that future behavioral research address system factors that fuel health disparities as a crucial barrier to optimal control of the epidemic. A similar recommendation was made on the programs to be implemented, which could address social determinants, such as poverty, education, geography, and socio-demographics, rather than just risk behavior. Biomedical research can also be more clearly defined, as current efforts, while adequate, do not take into account possible synergies with other federal agencies and other components within CDC.

B. Planning, Prioritizing and Monitoring

The Planning Panel inquired about the data that were used for planning and were unable to discern how much of the data gathered throughout DHAP for purposes such as surveillance and program evaluation informed planning. The Panel received information on the HIV Strategic Plan and cost-benefit analyses currently carried out by DHAP staff and emphasized the need for greater transparency on how decision-making is informed by available data. The Panel recommended that DHAP take steps to increase the transparency of the decision-making process and include input from external partners.

The Planning Panel emphasized the need for a National Plan for HIV/AIDS in the United States in which DHAP and CDC would assume a leadership role for the Department of Health and Human Services (HHS), other agencies within HHS, and other federal departments to inform an outcomes-oriented approach to HIV prevention that includes measurable goals, benchmarks, and accountability mechanisms. The Panel reiterated the need for CDC to work in collaboration with other governmental and non-governmental entities in the development of the plan and provide specific models that can be used for decision-making, including comparisons of the relative effectiveness of various activities as compared to each other and in comparison to no action.

The Panel stressed the need for CDC to report data on epidemic burden, population impact, programs implemented, program outcomes, and other relevant information in an annual report to be disseminated to the public. This annual report should make available to all interested parties information on the effectiveness of CDC’s activities in fighting HIV transmission. In the assessment of the Planning Panel, one of DHAP’s central priorities must be to increase public understanding of and support for primary HIV prevention activities in order to sustain and grow access to needed HIV prevention services in the United States and achieve needed reductions in HIV incidence and health disparities.

C. Surveillance

The Panel emphasized the critical role of the core HIV surveillance system, the keystone to HIV prevention and essential to HIV care and treatment programs. The capacity of and demands on the surveillance system have increased markedly over the past decade with the number of individuals living with HIV growing each year; confidential name-based HIV reporting just now implemented; the increasingly complex technology and requirements for electronic reporting, matching, and new data management systems; and expectations and opportunities for surveillance to support programs more actively. The core HIV surveillance system has never been evaluated against the established
performance standards. This evaluation, expected to be conducted in 2010, will likely illuminate strengths and deficits in the system’s ability to characterize the epidemic and support prevention and care programs. The Panelists recognized the unprecedented monitoring and prevention opportunities inherent in comprehensive laboratory reporting and encouraged CDC to support the jurisdictions’ capacity to implement such reporting systems. The panel noted CDC’s recent efforts to incorporate “supplemental” surveillance activities into Core surveillance processes; integration of such activities promotes more efficient use of resources and greater standardization of data. The panel viewed HIV surveillance as an integral component of CDC’s overall prevention portfolio and recommended that CDC reassess the role of surveillance and the adequacy of funding dedicated to this critical system.

Other overarching observations:

- The ability to conduct timely and meaningful data analysis to inform local program activities is challenged on many fronts across CDC’s HIV surveillance initiatives: some initiatives are not funded to support dedicated staff effort to ensure analysis and effective application of surveillance data to program; some surveillance activities may not be sufficiently robust to inform program locally (i.e., current HIV incidence surveillance system); additional guidance is needed about appropriate use of local data (i.e., core as well as incidence and resistance data); related initiatives have separate data management systems causing redundant effort and variable data quality; new data management systems are more complicated and require more advanced programming and analysis skills than in the past; many CDC personnel assigned to provide support to local jurisdictions are not sufficiently familiar with projects or best practices to provide meaningful assistance; CDC data analysis and information technology resources are strained.

- Advances in testing technologies necessitate ongoing review of their impact on surveillance activities such as: the case definition and case ascertainment processes, the ability to implement the current HIV incidence surveillance system and the validity of the current estimation methodology, opportunities to integrate incidence surveillance into routine surveillance if the time of infection can be ascertained reliably at individual level, the increasingly critical link between surveillance and prevention action to interrupt transmission that surveillance of acute and incident infections may afford.

- Lower morbidity jurisdictions are historically not represented in supplemental surveillance activities, and many report challenges with the increasingly complex data management and analysis needs.

- Closer collaboration is needed between program and surveillance to ensure most effective application of surveillance data to guide program; the use of GIS mapping to correlate HIV infection with other socio-economic and geographic characteristics may be an additional tool to develop.

- Greater integration and collaboration with the surveillance and program activities of related conditions, such as sexually transmitted diseases, tuberculosis, and hepatitis C is needed.

- Allocation of funding across the jurisdictions to conduct HIV surveillance activities does not appear equitable. The method for determining funding levels for surveillance activities should be assessed and made transparent.
The Surveillance Panel reviewed components of DHAP’s HIV case surveillance, HIV incidence surveillance, drug resistance surveillance, behavioral surveillance, and clinical surveillance programs. The participants noted strengths, weaknesses, and the unique contributions of each program in detail in the Surveillance Panel Summary section of this report.

D. **BIOMEDICAL INTERVENTIONS, DIAGNOSTICS, LABORATORY, AND HEALTH SERVICES RESEARCH**

The Panel reviewed information on current research and questioned how decisions are made within DHAP regarding the direction of research. The Panel discussed at length the role of the Laboratory, Epidemiology, and Behavioral and Clinical Surveillance Branches in conducting research that can result in useful data for program implementation.

The Panel observed that the prioritization process for funded research activities was not always based upon, nor linked to, broader division priorities. The Panel discussed what and how data was used to support the research agenda and how data from surveillance and program implementation was utilized to inform the direction of research. They recommended the creation of an internal scientific review panel to prioritize and align the decision-making process regarding the direction of research with the programmatic needs of DHAP. This panel would also oversee a thorough regularly scheduled ongoing review of research activities to ensure their applicability to current needs. In addition, it was recommended that DHAP convene an external panel of scientific experts at defined intervals to assess the effectiveness and appropriateness of the current scientific portfolio in relation to the HIV epidemic.

The Panel questioned whether the research being conducted, in developing assays and Pre-Exposure Prophylaxis (PrEP) was coordinated with other governmental and non-governmental organizations, such as pharmaceuticals, and whether this type of research was the appropriate role for CDC.

The Panel emphasized the need for greater collaboration and coordination within DHAP; with other CDC entities, including the Global AIDS Program (GAP); with industry; and with other federal agencies, especially the National Institutes of Health and the President’s Emergency Plan for AIDS Relief (PEPFAR).

The Panel acknowledged that the clear strength of the CDC scientific portfolio was in its translational work implementing science into public health practice. Yet, the Panel recognized the unique contribution of CDC research that did not fit into this translational category, including primate studies, health services research, natural history studies, and cost-effectiveness studies. The Panel recommended that in several of these areas, research could be enhanced and should be pursued.

E. **BEHAVIORAL, SOCIAL, AND STRUCTURAL INTERVENTIONS RESEARCH**

The Panel reviewed the research being carried out in the development of behavioral interventions and concluded that the past emphasis on demographics-based research has not resulted in interventions that address the individual level of risk and may have been counter productive in emphasizing race and ethnicity as factors that contribute to risk. The Panel emphasized in unequivocal terms the need to shift the focus of research to individual levels of risk. Among the
issues that can be considered in developing research methodologies are the following: practices, social factors, and behaviors that fuel HIV epidemics across populations and settings.

The Panel also emphasized that DHAP should engage in formative (Phase 1) research, which is an area where it has a good record and has collaborative relationships with practitioners, and operational (Phase 4) research, which studies the real world implementation of interventions derived from research. As the funder of prevention programs, DHAP and its partners would be better served in those areas of population and need definition and program implementation.

The Panel also questioned the effectiveness of the process to translate research into practice and evaluation data back to inform the research formulation process. Whereas there are extensive opportunities for collaboration and information sharing, the Panel believed that these were not sufficiently explored and carried out.

F. PREVENTION PROGRAMS, CAPACITY BUILDING, AND PROGRAM EVALUATION
The Program Panel emphasized that future prevention programs should address social determinants that have impact on risk behavior (poverty, racism, homophobia, incarceration, homelessness, substance abuse, immigration, and power inequities, among others).

The Panel also emphasized that gay, bisexual, and other men who have sex with men (MSM) should be given more attention in the development and implementation of prevention programs given their historic and current epidemic burden. The panel emphasized the importance of differentiating HIV prevention approaches for men who self identify as gay and bisexual and those who do not. Special emphasis should be given to transgender populations.

The Panel questioned the current structure of DHAP and whether it is responsive to the prevention needs of the populations at risk and whether a more streamlined structure would better serve those needs. The Panel indicated that it was not clear how and whether data from surveillance and epidemiology and program evaluation were used for the development of more effective programs.

The Panel recommended enhancing approaches to HIV prevention by including the funding of needle exchange programs, the reinforcement of abstinence and of consistent and correct condom use, and the use of social marketing strategies for the dissemination of information on HIV prevention.

Finally the Panel recommended a redefinition of the essential elements of a Comprehensive HIV Prevention Program, which are defined in the Supplemental Guidance for HIV Prevention Community Planning, to incorporate activities currently carried out by non-governmental organizations at the national and community-based level.
III. METHODS
In August and September 2008, the Centers for Disease Control and Prevention (CDC) published new data indicating that approximately 56,300 new HIV infections occurred in the United States in 2006. This figure is roughly 40 percent higher than CDC’s former estimate of 40,000 infections per year, indicating that the HIV epidemic is—and has been—worse than previously known.

Furthermore, new infections have been steadily increasing among MSM since the early 1990s, and the epidemic continues to have a disproportionately severe impact on African Americans and Hispanics/Latinos. Studies have found that many persons at risk for HIV infection are not being reached through current prevention efforts.

These findings have led the Division of HIV/AIDS Prevention to initiate a comprehensive review of its surveillance, research, program, and evaluation portfolios to ensure that they are appropriately configured to address the current epidemic. The review also meets the CDC-wide requirement for a Board of Scientific Counselors (BSC) administered external peer review of scientific programs, including research and non-research (i.e., public health practice), conducted or funded by CDC, to assess scientific and technical quality at least once every five years.

A. REVIEW PROCESS
An external review of DHAP’s HIV prevention portfolio was discussed at an open session where Kevin Fenton, M.D., Director of NCHHSTP, and Richard Wolitski, Ph.D., Acting Director of DHAP, presented at the United States Conference on AIDS in September 2008. Such a review was seen as an initial step in developing DHAP’s response to the revised numbers of new infections reported at the International AIDS Conference in Mexico City. The External Peer Review (EPR) described in this report was initiated to address this need. The EPR process consisted of selecting a group of external reviewers with extensive experience in the area to be reviewed, the development of a series of guiding questions to steer the review into areas that can provide meaningful input to CDC, the selection of the Peer Reviewers, development of briefing materials on the activities to be reviewed, presentation of these materials, and providing a forum for review and discussion.

The peer review was to obtain external feedback on DHAP’s HIV prevention programs, including research and non-research. The review addressed DHAP’s entire range of activities, including strategic planning and prioritization; surveillance programs; biomedical intervention and laboratory research; health services and operational research; behavioral, social, and structural intervention research; health department and community-based organization programs for HIV prevention; social marketing activities; capacity-building assistance; and program monitoring and evaluation.

The following aspects of the program were to be addressed:
- Relevance to DHAP’s mission
- Scope and prioritization
- Scientific and technical quality, approach, and direction
- Adequacy of translation and dissemination of research findings for use in programs
- Strengths, gaps, challenges, and opportunities
• Extent to which the program addresses the National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) programmatic imperatives of program collaboration and service integration, reducing health disparities, and maximizing global synergies

Samuel Dooley, M.D., Associate DHAP Director for Science and Program Integration, was charged with the responsibility of leading the review planning and implementation. In this role, Dr. Dooley chaired an internal Peer Review Planning Committee that was entrusted with supporting the external review. The process was divided into five areas, and each area was assigned a staff liaison from the leadership at DHAP:

Steering Committee  Samuel Dooley, M.D., Associate Director for Science and Program Integration
Planning  Chris Cagle, Ph.D., Associate Director for Policy and Planning
Surveillance  Amy Lansky, Ph.D., M.P.H., Acting Deputy Director for Surveillance, Epidemiology, and Laboratory Science
Biomedical  Bernard “Bernie” Branson, M.D., Associate Director for Laboratory Diagnostics
Behavioral  Cindy Lyles, Ph.D., Acting Deputy Director for Behavioral and Social Science
Program  Janet Cleveland, M.S., Deputy Director for Prevention Programs

This DHAP Peer Review Planning Committee came together for weekly meetings to accomplish the following tasks:
1. Reviewers: submit names of experts in the five areas for inclusion in the External Peer Review
2. Questions: provide input on the questions to be developed to guide the process
3. Briefing: coordinate with the Division and the various Branches to obtain the briefing materials to be submitted to the EPR panel members
4. Presentation: coordinate with the Division and the various Branches to develop presentations to be made in person to their respective panels during the EPR meeting
5. Resource: serve as a resource to their panels and answer questions as appropriate
6. Response: coordinate the DHAP response to the findings and recommendations of the respective panels

B. Reviewer Selection Process

The DHAP Peer Review Planning Committee was interested in inviting a group of individuals with experience in HIV Prevention and CDC activities who would be able to provide input to CDC. In order to accomplish this, the committee considered that it was important for the reviewers to have a prior understanding of CDC’s activities and would be able to articulate feedback useful to DHAP. The DHAP Peer Review Planning Committee proposed criteria for selecting EPR Panel members, including the following:
• Knowledge of CDC activities and programs
• Experience in HIV prevention
• Experience in similar processes in the past
• Racial, ethnic, gender, and geographic diversity, and membership in populations historically served by CDC’s programs
• Governmental and non-governmental experience: individuals from state and local governments; academia; and community-based and national organizations, including long-standing partners of DHAP
• Former CDC employees were considered eligible only if they had left CDC at least two years prior to being invited to participate in the review

The Planning Committee decided that approximately 70 reviewers would be ideal so that each of the review panels could consist of approximately 8–12 participants and two Co-Chairs. The Co-Chairs for each panel would also come together as a steering committee, which would be chaired by the overall EPR Chairs.

Selecting reviewers was challenging because so many people have a strong interest in HIV prevention and have expertise in the areas being covered by the review. DHAP staff, including the Director and Deputies, Associate Directors, and Branch Chiefs, were queried for suggestions, as was the NCHHSTP Office of the Director. Branch Chiefs encouraged their staff to make recommendations. Names of health department HIV program directors and surveillance coordinators were solicited from the National Alliance of State and Territorial AIDS Directors (NASTAD) and the Council of State and Territorial Epidemiologists (CSTE). An effort was also made to include members of the BSC and the CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment (CHAC).

A workgroup for each of the five review areas evaluated and prioritized the names that had been suggested. Once nominees were identified and prioritized, the list was reviewed to ensure sufficient diversity. Final prioritization of nominees was done by the DHAP Division Director, Deputies, and Associate Directors, using the same criteria listed above.

C. CHAIR AND CO-CHAIR SELECTION PROCESS

The Chairs of the process were entrusted with leading the reviewers to provide input to CDC that would be meaningful in the future. The Chairs were to be able to describe to the panel members and Co-Chairs the purpose of the process and maintain the necessary focus in developing findings and recommendations and serve as Chairs of the Steering Committee, whose role would be to synthesize the input from the various panels into overarching recommendations. In order to achieve this, DHAP sought two individuals with extensive and in-depth knowledge of DHAP’s activities who had preferably previously served in an advisory capacity.

After an extensive vetting process, DHAP appointed Edward “Ned” Hook, M.D., and Jesse Milan, JD, to serve as overall Chairs of the process. Dr. Hook is a professor of public health at the University of Alabama at Birmingham; has extensive experience in the area of HIV prevention, surveillance and epidemiology; and currently serves as Co-Chair of the CDC/Health Resources and Services Administration (HRSA) Advisory Committee (CHAC). Mr. Milan, who is a person living with HIV for 27 years, served as AIDS Director for the City of Philadelphia, and is currently Vice President for Community Health Systems of the Altarum Institute. He served for five years as Co-Chair of the CHAC, has served as Board Chair of four nationally recognized AIDS organizations, and was project director of the CDC’s National Prevention Information Network (NPIN) for seven years.
The Co-Chairs for the various panels were also selected based on their extensive experience with CDC programs, having participated in similar processes to provide input to CDC in the past, and reflected diversity in terms of organizational affiliation, geography, and demographics. The depth and breadth of experience is reflected in the selections made for the various panels as follows:

**Planning**

David Holtgrave, Ph.D.  
Johns Hopkins Bloomberg School of Public Health  
Julie Scofield  
National Alliance of State and Territorial AIDS Directors  
David Ernesto Munar  
AIDS Foundation of Chicago

**Surveillance**

Douglas Frye, M.D.  
Los Angeles County Dept of Public Health  
Amy Zapata, M.P.H.  
Louisiana Office of Public Health

**Biomedical**

Kenneth Mayer, M.D.  
Brown University/The Miriam Hospital  
Mark Thrun, M.D.  
Denver Public Health

**Behavioral**

Cynthia Gomez, M.Ed., M.P.H.  
San Francisco State University  
Seth Kalichman, Ph.D.  
University of Connecticut

**Program**

Marjorie Hill, Ph.D.  
Gay Men’s Health Crisis  
Beth Meyerson, M.Div., Ph.D.  
Policy Resource Group, LLC

---

1 Mr. Munar agreed to serve as Co-Chair of the Planning Panel when David Holtgrave was unable to attend in person. Dr. Holtgrave participated via telephone.

---

D. **GUIDING QUESTIONS**

In order to address the purpose of the EPR, DHAP staff proposed the development of a list of guiding questions, which would be presented to the EPR Reviewers prior to the meeting, and could be used to develop briefing materials and presentations. The questions (see Appendix C) represent the general areas where DHAP staff seeks input regarding programs and activities. The DHAP Liaison Committee guided the process by which the various Panel Liaisons worked with other staff to develop questions specific to each panel and provide input on questions for the Steering Committee. The questions sought to address the following issues regarding DHAP programs and activities among others:

- Scientific validity and quality of programs and activities
- Appropriateness of activities to address the need identified
- Appropriate application of resources
The questions received extensive vetting from DHAP staff and from NCHHSTP leadership. Once finalized, the questions set the framework for the development of briefing materials that would assist the EPR Panel members to answer their respective questions.

E. **Briefing Materials**

In order to prepare for the review, DHAP staff prepared an extensive compilation of materials that would provide information to inform the process. The materials, which included information on current projects and activities and a description of the operating context of DHAP, consisted of two major components:

- **Briefing book**: an exhaustive compendium of approximately 700 pages, which contained information on the EPR process, the state of the HIV/AIDS epidemic in the United States, the DHAP organization and funding, the role of DHAP in the federal effort to address the HIV/AIDS epidemic. The book also contained various sections to address each panel’s topic areas in detail, including a description of the organizational units (branches), projects carried out, and narrative and funding for each project. The briefing book was made available in hard copy and CD-ROM ahead of the meeting.

- **Presentations**: DHAP staff prepared various slide presentations containing some of the more salient information related to the various panels, including the vision, mission, goals, objectives, and current status of some of the more significant projects and activities. The presentations were to be made by DHAP and Branch leadership to provide an opportunity for questions and answers regarding the information presented and to clarify any issues raised during the panel discussions.

F. **Conference Calls**

DHAP staff coordinated various conference calls with the EPR Chairs to review the process, provide information on the steps to be carried out, and describe the expected outcomes. Rich Wolitski, DHAP Acting Director, led a conference call with Sam Dooley, EPR Planning Lead; Jesse Milan; and Ned Hook to thank them for agreeing to chair the process and to describe the charge to the reviewers, the structure of the EPR meeting in April, and the report development process.

At this and other conference calls, the Chairs and Co-Chairs were able to obtain clarification regarding the process and discuss the process to be used for arriving at findings and recommendations. The Chairs expressed reservations as to whether the Steering Committee would be able to synthesize the discussion of the various panels and answer their own questions on the last day and emphasized the need for the Steering Committee to come together repeatedly to review progress in the various panels.
The Chairs also raised the issue that each panel should decide whether CDC staff would remain in the room during the proceedings. While CDC staff would be available to answer questions, there was a concern that their presence during the discussion may distract the reviewers from the topics to be covered.

The Chairs sought clarification on the level of specificity needed from the Steering Committee and learned that it was CDC’s request that the discussion be at a high level rather than project by project and that there was no expectation that the Steering Committee provide input on reallocation of resources. The feedback was expected to address priority activities, groups and types of activities to be continued and expanded, and those that should be phased out or discontinued.

G. EPR MEETING

The full group of reviewers convened on April 13–15, 2009, in Atlanta, Georgia. The reviewers attended an opening plenary session that addressed the current status of the epidemic; the role of DHAP relative to other entities involved in HIV prevention; and DHAP’s mission, goals, strategic priorities, organization, and budget.

Following the opening plenary session, the group divided into the five panels, where DHAP senior staff members gave presentations to provide additional information relevant to that panel’s specific subject areas and answer clarifying questions from the reviewers. Following the presentations, reviewers had ample time to discuss the questions that were posed to their panel and to begin work on their panel’s report and recommendations. DHAP senior staff was available to the panels to address questions that arose throughout the meeting. The meeting concluded with a plenary session in which all reviewers had an opportunity to hear summaries of the major themes and tentative recommendations emerging from each of the panels. The Steering Committee met at lunch and at the end of the second and third days to address its own questions.

H. ADOPTION OF GUIDING QUESTIONS

As a starting point in the discussion of the various panels and the Steering Committee, the reviewers had to agree on the process to follow, which began with the review and adoption of the questions to be addressed by each of the panels. The panel was able to determine which questions, if any, would be adopted and addressed as part of the discussion. The panels and the Steering Committee were aware that they could adopt, amend, supplement, or discard the questions as appropriate. For the most part, the panels and the Steering Committee addressed the questions as originally posed. Changes to the questions are noted in the individual panel reports.

I. DISCUSSION

Each of the panels adopted the discussion mode the members preferred, generally addressing the issues specifically raised in their questions, including issues related to those under discussion, and asking questions of CDC staff to clarify specific points. The Co-Chairs facilitated the discussion and focused the input into specific findings and recommendations as included here. Each panel was provided with a notetaker who took down questions, issues raised, and the more salient points of the discussion. The various panels were also tape recorded in order for a qualitative data analysis to be carried out, to ensure all relevant points were captured, and to analyze for themes and commonalities among the panels.
J. REPORT DEVELOPMENT

Subsequent to the meeting, the Co-chairs of each panel continued work on their panel’s report and recommendations with input from panel members. The Steering Committee, under the direction of the two overall Chairs, oversaw the process of integrating the five panel reports into a single, comprehensive report that also addressed cross-cutting issues. This report was developed through a three-step process:

1) **Review and Synthesis of Notes:** the notes from the various panels, Steering Committee and plenary sessions were used as the basis of the report, which included the compilation, harmonization, and condensation of the discussion. The notes were converted to bullets and organized under the questions to which they referred in order to address the issues within the purview of the panel or Steering Committee.

2) **Qualitative Analysis of Panel and Plenary Discussion:** the transcripts of the panels and Steering Committee were analyzed to determine if any important issues were not included and to analyze commonalities and themes among the panels.

3) **Review and Input from Chairs and Co-Chairs:** various drafts of this report were presented to the Chairs and Co-Chairs for their review and comment.

4) **Supporting Materials:** background materials were added, which also received input from the Chairs and Co-Chairs, and appear as part of this section and in the appendix.

K. PRESENTATION TO DHAP AND BOARD OF SCIENTIFIC COUNSELORS

Once completed and adopted by the EPR Reviewers, this report was presented to DHAP. DHAP staff prepared a programmatic response to address the issues raised and what steps would be taken to address the findings and recommendations included herein.

The final report was presented to the Board of Scientific Counselors of the Coordinating Center for Infectious Diseases at its meeting in November 2009 for its comment and final approval.
IV. STEERING COMMITTEE

Chaired by the overall EPR Chairs and composed of each of the panel Co-chairs, the Steering Committee was a leadership trust for the ERP and provided a forum for sharing and integrating process and substantive issues occurring throughout the review. Over the course of the meeting, the Steering Committee met twice daily to clarify procedures, share emerging insights on common themes, and transfer lessons learned. The two overall Chairs divided the five panels between them to monitor their process and deliberations and offered support and clarification when needed.

On the final day, following the summary presentations by each of the panels, the Steering Committee reconvened to address the specific, crosscutting guiding questions assigned to it. The overall Chairs proposed a process that would respect the unique expertise of the panel Co-chairs and encourage their discourse as peers. The overall Chairs reviewed the proposed questions with the Steering Committee and asked the members to determine whether any additional issues should be added or questions be further refined. To address the questions, the panel Co-chairs whose subject matter was most related to each question were asked to provide their responses first. Thus, one by one, the most relevant expert perspectives lead the committee’s discussion of each question.

After the panel Co-chairs provided their responses, the remaining Steering Committee members were invited to validate or offer differing or additional perspectives. Questions were addressed in order in a step-by-step fashion with each of Co-chairs from the topic panels providing their perspective in sequence. Out of this process, a norm of consensus emerged in the Steering Committee with broad peer affirmation or concurrence of lead expert opinions, coupled with committee members’ additions or refinements. Most notably, no exceptional disagreements were expressed for the themes, guidance, and recommendations summarized below.

Surveillance. There was strong consensus in the Steering Committee that the CDC plays a unique and central role in public characterization of the epidemic and its impact. In addition, the Steering Committee recognized that the surveillance system also has a potentially important role to play in supporting direct prevention efforts, such as partner services. However, as the epidemic and prevention efforts and approaches have evolved, surveillance has not evolved in parallel, thereby introducing new challenges for the surveillance branch. Surveillance activities should first and foremost emphasize the evolution of the epidemic and its impact (i.e., case numbers, new infections, and associated behavioral, sociodemographic, and geographic risk factors). As critical as the surveillance function is, there was consensus that efforts were needed to make surveillance data available more quickly and to ensure that these data were used to shape local intervention efforts.

Priority Setting. The Steering Committee expressed strong uniform concern that there is no public understanding or knowledge of DHAP’s priority setting and decision-making process. Despite explanations in the background document about the annual DHAP retreat, the Steering Committee did not recognize that event as a transparent priority-setting process. Neither the Steering Committee nor many of the DHAP personnel who presented data at the EPR meeting could clearly articulate the manner in which program or resource priorities were set, either in the Division as a whole and within the individual branches. This lack of decision-making transparency was a great concern of the Steering Committee. The Steering Committee recommends that an improved and more transparent process be identified and used by DHAP.
Intra-Division Communications. Communications between DHAP leaders, especially between the program and research branches and between the program and surveillance branches, need improvement. These communications issues raise concerns about the timely translation of surveillance and research findings into DHAP programs and public health practice and about how perspectives from practice and program arenas infuse research priorities and surveillance requests. Internal communications issues also raised concerns about overall coordination and collaboration within DHAP and among offices and branches both in Atlanta and in the field.

A. Topics Addressed

- Current mix of activities across populations and mission areas
- Current resource allocation across populations and mission areas
- Translation and dissemination of research findings

B. Proportion of Activities

How proportional is the current mix of DHAP’s programs and activities to the needs of its priority populations?

- The SC agreed that the current focus based primarily on population demographics is no longer sufficient and that there should be additional emphasis across all populations based on behaviors and the context in which risk behaviors occur. At the program level, the SC believes that targeting by race/ethnicity alone is stigmatizing and limiting and, while a possible mechanism for allocation of resources, is focused on immutable characteristics of persons at risk and does not adequately prioritize persons of all backgrounds whose behaviors and/or context (social networks, prevalence, co-occurring factors, etc.) place them at risk.

- The SC strongly recommends that new strategies and interventions be developed based on social determinants of health (e.g. poverty, education, geography), including issues related to MSM and injecting drug users. The SC recommends specifically that new combination strategies emphasize the role of social determinants in addressing risks for gay men, including the issues of societal, institutional, and internalized homophobia.

- The SC recommends that DHAP programs and activities be tied to clear outcomes. The SC specifically recommends that number of infections averted should be identified as a specific outcome measure. Outcome measures articulated by the President’s Emergency Plan for AIDS Relief (PEPFAR) could be used as models.

- The SC emphasized that the question should not be whether the appropriate portion of prevention services is being devoted to specific populations but whether populations at greatest risk receive the appropriate level of prevention services.

- The SC expressed concern regarding the proportionality of resources for low prevalence areas and questioned whether adequate resources were devoted to their populations. Specifically, the SC recommends that DHAP reconsider the appropriateness of requiring low prevalence areas to undertake the same activities as higher prevalence jurisdictions without adequate infrastructure, capacity, and resources.
C. **APPROPRIATENESS OF ACTIVITIES**

**How appropriate is the current mix of activities across mission areas (i.e., surveillance, research, program, capacity building/technical assistance, and evaluation)?**

- The SC agreed that there is a need for more resources for surveillance activities, especially for core surveillance, due to an increase in national prevalence and due to the greater amounts of data being reported to and analyzed by the CDC and utilized by other federal agencies such as HRSA.
- The SC agreed that from a planning perspective, the current mix is not sufficient. The SC recommends improved capacity at the national level for planning and for translation of strategic objectives into operational plans. The SC also recommends creation of an annual report card showing progress to attain strategic goals, objectives, and outcomes.
- The SC agreed that there are insufficient resources for the research program at DHAP. The SC recommends that given resource limitations, clearer research priorities should be set and research activities should focus on those priorities.
- The SC recommends that DHAP have more effort devoted to the translation of research into practice, that these efforts be timely, and that practice observations should be used to better inform the DHAP research agenda. The SC recommends translational research be prioritized in contrast to the current “topic-based” research strategy.
- The SC recommends that DHAP expand the cultivation of grassroots interventions being used by community-based organizations (CBOs) and document successful grassroots interventions for replication. The SC recommends that DHAP quickly expand the number and types of approved interventions to more fully develop the prevention portfolio available for dissemination and to better serve the variety of prevention constituencies. The SC specifically recommends developing more interventions using communication strategies, social marketing, and structural interventions, which are currently inadequate.
- The SC noted that capacity-building support for indirectly funded CBOs is currently inadequate and should be improved.

D. **RESOURCE ALLOCATION**

**How appropriate is DHAP’s current allocation of resources across mission areas?**

The Chairs recommended reframing this question into two separate but related questions:

**Is the allocation for DHAP appropriate? Is DHAP’s current allocation of resources across mission areas appropriate?**

The Committee offered the following analysis and recommendations:

- General allocation needs to be aligned with DHAP priorities and translated into outcomes across programs.
- The SC agreed that it is important that DHAP’s activities be based on available surveillance data, and that DHAP ensure that its activities match the nation’s prevention needs. However, the SC expressed that it had no confidence in the current match.
• There is some difficulty in assessing this question due to internal inefficiencies and redundancies, and overlaps in areas, including research and surveillance. Nonetheless there are not enough resources, even in light of DHAP’s inefficiencies and redundancy.

• The SC recommends that HIV/AIDS resources across CDC be included in any review of resource allocation. The agency should ensure that all HIV/AIDS-related resources allocated to other parts of CDC are used consistently with DHAP’s strategic priorities and goals or be allocated to DHAP for use in achieving DHAP’s national goals for HIV prevention.

• The SC strongly recommends that DHAP’s priority-setting and decision-making processes become more transparent and public. The SC noted that some DHAP activities appear to be carried out merely as a continuation of existing activities that may no longer be relevant, while new areas are not getting sufficient attention. Without clearer and more transparent priority and decision-making processes, these perceptions will continue.

• Support for core public health functions, such as surveillance and evaluation, need to be bolstered and safeguarded. The SC noted that in surveillance, resources for core infrastructure have been level funded even as circumstances change. This is unacceptable.

• New areas of research on interventions, such as structural interventions to address social determinants and social marketing, do not have adequate resources.

• In terms of behavioral research, current resources are insufficient, and they should be allocated to different research priorities (e.g. more translational research, the effects of social determinants on health behavior, and study social marketing efforts), and allocations should support greater interaction with health departments and work with non-government researchers.

• The SC also noted that low morbidity areas could use DHAP or CDC technical assistance support to learn strategies to carry out their CDC requirements within their current limited resources. SC recommends that CDC address these concerns.

• The SC pointed out that there are public and internal expectations of collaboration and coordination within DHAP, but the DHAP Office of the Director (OD) does not have resources and staff to carry out this function. Additional allocations should be made to strengthen collaboration and coordination.

• There are multiple possible synergies among prevention programs and science and research projects that can be achieved through greater interaction among the various divisions in addition to those that can be achieved within DHAP. Some synergy may be achieved if collaboration is required of funded activities.

• There is a need for stronger leadership to address cost efficiencies. There is a need for a thorough assessment of what is not working, for greater support for enhancing infrastructure at the community and health department levels, and to address social determinants of health.

E. KNOWLEDGE TRANSLATION AND DISSEMINATION

How adequate are DHAP’s efforts at translating and disseminating research findings and incorporating new knowledge into action?
• Overall, the SC found that DHAP’s efforts at translating and disseminating research and incorporating new knowledge into action are inadequate in relation to the scope of the national HIV epidemic.
• The SC recommends that DHAP improve internal collaboration (especially between program and research branches) in the planning and implementation of any research project. The Task Force model can be used for coordination of efforts and more effective translation of findings, which is something DHAP does very well.
• The Capacity Building Assistance (CBA) model, which works via national, regional and local technical assistance organizations, should be better evaluated to determine its effectiveness.
• The Diffusion of Evidence Based Interventions (DEBIs) has relied on the gathering of evidence-based approaches that are not uniformly adequate or helpful to the implementers at the community level. While the model has helped CBOs increase the science base and formal structures of their interventions, the model has been limited in reach and application. The SC recommends that additional strategies targeting specific populations be created to make the DEBI portfolio more comprehensive and more effective. Examples include, but are not limited to, evidence-based social marketing initiatives and evidence-based structural interventions.
• DHAP must create stronger linkages between researchers and practitioners to exchange information on science and implementation.
• Many community-level prevention practitioners have been able to develop successful interventions within their programs, and these “homegrown” interventions would be useful to expand the scope of DHAP-approved or funded prevention activities. The SC strongly recommends that these interventions should be evaluated, expanded, cultivated, and offered widely.

F. Capacity and Resources
To what extent does DHAP have adequate capacity and sufficient resources to address its mission, goals, and priorities?

• Current capacity is not adequate, and additional funding is required to support core public health functions, such as surveillance, evaluation, and program development.
• The SC did not have sufficient information on what was being funded to determine whether resources were applied in the right proportions. The information in the Professional Judgment Budget provided useful guidance, but was not the definitive answer as to what additional resources are needed. However, the SC strongly recommends that the Professional Judgment Budget be used as the starting point for planning for the future.
• The SC recommends improvements in DHAP business management. DHAP is not effectively supported and is sometimes hampered by the Procurement and Grants Office (PGO). In addition, the SC recommended that DHAP leaders and branches receive additional skills, guidance, and staff capacity to manage effectively the size and variety of business processes and funds entrusted to them.
G. **PROGRAM GAPS**

**What are the principal gaps in DHAP’s programs overall?**

- There is very little use of data from other disease surveillance systems to inform program planning or prevention approaches for HIV. DHAP is not fully prepared for addressing HIV prevention in a changing health care environment; it is not prepared to represent HIV prevention perspectives in health care reform discussions; and it is unprepared for responding to health care changes in the future should health care reform become a reality.
- The SC found that DHAP’s use of technology for prevention is inadequate, and DHAP has played an inadequate role in assessing and incorporating new technology.
- The SC recommends more timely collection and dissemination of data gathered through surveillance and evaluation back to programs at the state and local levels so that the information can be used more quickly for program improvement.
- The SC recommends enhancing health services research that goes beyond cost-benefit analyses and planning and that goes beyond a mere comparison of new activities and the absence of activities. The SC noted that optimization modeling can be useful in this regard; as can standard cost-effectiveness analyses in which multiple policy/program options are compared to each other, rather than compared just to the status quo.
- The SC suggests that DHAP pursue new methodologies that address prevention from a holistic perspective, where the individual can be viewed from various angles by practitioners and structural interventions developed to meet the individual’s various prevention needs.
- A significant gap in DHAP programs is its ability to provide adequate support for programs and jurisdictions in rapidly scaling up effective interventions (or sets of interventions) and testing initiatives to meet growing needs and opportunities. SC recommends that this serious gap be addressed and remedied.

H. **CDC ROLE**

**What is DHAP’s unique role in HIV prevention within CDC?**

The SC recommended combining the two sections on DHAP’s role for HIV prevention within the CDC and in the United States into the following two sections.

I. **UNITED STATES ROLE**

**What is DHAP’s unique role for HIV prevention for the United States?**

The SC recommended combining the two sections on DHAP’s role for HIV prevention within the CDC and in the United States into the following two sections.
J. **STRUCTURE AND OPERATIONS**

Are DHAP’s intramural organizational structure, operations, and business management functions efficient and appropriate?

- The SC stressed that there must be a significant streamlining in the contracts, grants, and cooperative agreements approval process within the PGO. DHAP’s timeliness and effectiveness is significantly hampered by the inadequate or unhelpful processes, resources, and support of PGO. The SC also noted that PGO appears to make frequent decisions that have direct programmatic impact and that PGO does not consistently defer to program expertise regarding substantive programmatic matters.

- The SC expressed serious concerns regarding the internal culture of CDC and DHAP. The SC noted persistent clashes between “science” and “program/community” perspectives; between staff with medical doctor versus Ph.D. degrees; and between “biomedical” and “behavioral” prevention perspectives. The SC recommends that these conflicts be assessed and addressed because they may prevent the implementation of innovative practices and because they may limit the useful exchange of information and ideas between programs, branches, and staff.

- The SC also noted perceived clashes between “top-down” vs. “collaborative” priority-setting and decision-making within DHAP. This clash was perceived by the SC as a major barrier to DHAP operational effectiveness. The SC recommends that this issue be assessed and addressed as well.

- The SC further noted that the current emphasis on staff publishing also may hamper DHAP’s effectiveness, as it diverts attention away from immediate programmatic concerns (although it is necessary to add credibility to CDC’s work).

- The SC recommends that CDC reconsider and eliminate the Coordinating Center structure. The SC noted that this structure is a drain on division-level resources and has not demonstrated a useful purpose. The SC unanimously voiced that it should be removed.

- The SC expressly agreed that there should be better coordination with the Global AIDS Program (GAP) to avoid duplication of effort and DHAP staff and resources going to GAP.

- The SC endorsed CDC’s reconsideration of the operational prominence of DHAP and assess whether DHAP should be a standalone Center for HIV/AIDS Prevention within CDC. The SC expressed concerns about the existence of two operational units that operate as DHAP and recommended that the impact of this dual structure on paper be examined in order to ameliorate its impact on operations. The SC also questioned the wisdom of domestic and global activities being separate and how this bifurcation impacts coordination of activities and collaboration. The SC suggests that CDC explore combining DHAP and GAP into a single Center for HIV/AIDS Prevention.

K. **CDC STRENGTHS**

What are the unique strengths that CDC brings to the national prevention agenda?

- The SC noted that CDC, through its data gathering capacity in the areas of surveillance, behavioral, and biomedical research, can bridge science into practice in ways no other federal agency can. When coupled with its ability to provide funding to external partners
and provide leadership, the agency is uniquely positioned to fundamentally impact public health practice.

- The Community Planning Process has been successful in integrating voices of the health departments and the community to a concerted planning process. The SC recommends that CDC incorporate the principles of community planning in its own planning processes.
- CDC has the unique ability to mobilize public opinion to HIV prevention with great authority. The SC expressed their desire for CDC and DHAP to bring more voice to HIV prevention in the United States and to address underlying issues such as stigma and discrimination.
- CDC can also bring researchers and practitioners together to set priorities for research and to obtain evaluation data on program effectiveness.
- It is DHAP’s unique role to prevent HIV transmission in the United States. In order to accomplish this, CDC must anticipate the trajectory of the epidemic and set up an effective prevention framework to anticipate and respond to the future trajectory of the epidemic.
V. PANEL SUMMARIES

A. PLANNING, PRIORITIZING, AND MONITORING

The Planning Panel was briefed on the processes by which DHAP plans programs and activities, including the analysis conducted to determine the cost-benefit of the implementation of various activities. The panel also reviewed information on budget allocations, the decision-making process within the Division, and the National Program Monitoring and Evaluation process currently underway. The panel provided extensive input on the planning role of DHAP, not only for its own activities within CDC, but also in the future as the administration prepares to develop a National HIV/AIDS Strategy (NHAS).

Overarching recommendations were identified by the Planning Panel that do not relate directly to any particular review question but are important to include. The panel felt strongly that CDC DHAP leadership on domestic HIV prevention is needed now and that as the lead public health, science-based prevention agency in the nation, CDC DHAP should be the nation’s voice on HIV prevention. The panel emphasized the expectation that CDC DHAP will play a leadership role in the development of a National HIV/AIDS Strategy (NHAS) as well as a significant monitoring role that the panel recommends include making public how we are doing as a nation in meeting the objectives and goals of the NHAS (e.g., a national report card, the HIV state of the union).

A second significant recommendation from the panel is that DHAP be forward-thinking and future-oriented in its planning, resource allocation, and evaluation of its efforts with the goal of preventing as many new HIV infections as possible as the primary guiding principle. The concept of “combination prevention” was endorsed along with the recognition that to be successful, the nation needs to scale up significantly the coverage, scope, and intensity of HIV prevention in the United States. For planning purposes, the panel recommends an approach which includes the development of several different funding scenarios—what is likely to be achieved with current resources, with increased resources, and with decreased resources. The cost of failure to act must be considered.

The importance of greater transparency on planning and prioritization processes was stressed. Prior strategic planning efforts have not been well understood, and it was unclear to some panelists how they came to be, what data informed them, and who did and did not have influence on their development. In addition to greater transparency on future planning efforts, the panel recommends that the expertise of CDC staff be used more effectively in future planning. It was also noted that the goals and objectives in prior plans have not always been specific, measurable, achievable, and/or realistic within the specified time frame and with actual resources in mind.

The panel questioned whether or not DHAP used its own data to plan and evaluate its efforts effectively at the Division level and across all of the various Branches. The panel recommends that the Division develop clear ways of taking stock of what is happening internally, externally, and relative to set objectives on an ongoing basis. DHAP should develop data-utilization plans and look at what is needed to make decisions at the Division level. The panel recommends one simple, integrated nimble (prepared to act quickly) system that is geared toward strategic decision-making and the dissemination of appropriate and timely information for actionable use internally and externally.
Greater efforts should be made to maximize learning via the Division’s monitoring and evaluation activities. DHAP should develop evaluation questions that are better tied to strategic decisions and initiatives. Questions should change over time as appropriate, reflect goals and objectives and, where possible, be prospective. Attention must be made to improve the quality of the indicators and the data collected to reflect those indicators. DHAP’s indicators should be adequately specific, capturing important pieces of information (cost, unintended consequences), or clearly linked to process and outcome objectives at the division and program level. Information should be used to determine success and improve decision-making and implementation of DHAP efforts.

The panel felt strongly that CDC DHAP needed to have a stronger voice in policy beyond its accepted processes of guidance and recommendation development. DHAP needs to become an astute user of the existing public policy mechanisms, including budget, legislation, regulations, and public affairs, and assist state, local, and directly funded grantees in translating policy data and scientific analysis into action. DHAP should provide the public with easy access to information, translated in a user-friendly way. Finally, the panel acknowledged the need for CDC to be both nimble and transparent in order to ensure stakeholder buy-in and support.

Topics to be addressed:

- Strategy development and planning
- Priority setting (including Resource Allocation Model)
- Results monitoring (esp. DHAP monitoring and evaluation plan)

1. **To what extent are DHAP’s processes for planning, strategy development, and priority setting explicit and technically valid?**

   - The panel requested clarification on how the strategic plan translated into an operational plan. Not all the panel members were aware the HIV Strategic Plan had been extended to 2010.
   - The panel also wanted clarification on the distinction between the Strategic Plan and the Professional Judgment Budget, the latter’s development, who will be served, and how progress will be measured.
   - The panel requested specific information on DHAP’s policymaking role, including how processes work within CDC for engagement with HHS, the Office of Management and Budget (OMB), and Congress and what limitations and boundaries exist, with a particular focus on the budget process. The panel further inquired as to what authority, including statutory authority, DHAP would require to be better engaged in policymaking processes.
   - The panel recommended DHAP focus on its own organizational functions as a basis for future plans, avoid duplication of effort, and provide rapid response to emerging issues. DHAP can also have a broader scope for planning and use input from within the Division.

2. **To what extent do these processes make adequate and appropriate use of data?**

   - It was not entirely clear to the panel what data were used to inform planning and whether or that not all of the data that might inform planning were being brought to bear on planning.
The panel suggested that CDC take stock of its potential data sources and their potential value for planning and evaluation at the Divisional level.

- The panel noted the lack of sufficient evaluation data on capacity-building efforts, including evaluation data on the tailoring and adaptation of the evidence-based interventions.

3. How might DHAP best incorporate external input into its planning, strategy development, and priority setting?

- The panel recommended that stakeholder involvement occur at various stages in order to achieve buy-in into the planning outcomes. External nongovernmental stakeholders expect CDC to lead a planning effort that includes stakeholder input with the optimal goal of gaining external support for DHAP programs and priorities.
- On a wider plane, the panel emphasized DHAP’s role in fostering a better understanding of HIV prevalence and its impact on future infections (e.g., via changing HIV transmission rates which depend on both incidence and prevalence). The panel stated the importance of CDC making strong leadership statements that would garner community support. The panel indicated that the purpose of the plan must be clearly stated.
- The panel underscored the need to have members of the CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment better understand the structure and operations of DHAP in order to be better prepared to monitor and make recommendations regarding DHAP activities.

4. What are the strengths and weaknesses of these processes and what are your recommendations for improving them?

- The panel emphasized the need to anticipate future needs in HIV prevention with planning based on surveillance and epidemiology data, prevalence and transmission rates. Planning efforts can be organized according to prevalence, with high-, moderate-, and low-prevalence jurisdictions, and with special consideration of populations and jurisdictions with estimated low prevalence of HIV (Asian/Pacific Islanders, Native Americans/Alaska Native, U.S. Virgin Islands and Pacific Territories). The panel recommended creating a working group to provide input on future challenges. This panel could be charged with creating a policy- and program-relevant “dashboard” of the HIV epidemic suitable for timely and comprehensive program planning and evaluation.
- The panel provided several recommendations regarding planning with a particular focus on funding allocations.
  - The panel recommended that several effectiveness analyses be used in planning including, the number of new infections that could be averted with a) current resources, b) incremental increases in resources, c) increases based on documented need, d) level funding, e) no change (or the consequences of failing to act). Planning can also look at the marginal utility of additional funding to maximize its impact.
  - The analyses can support funding in other agencies and for activities not covered elsewhere. Planning can be based on overall funding for HIV activities (i.e., treatment and research). Planning may result in goals that go beyond the current parameters, while other goals may be more achievable.
5. **How appropriate and relevant are DHAP’s strategic priorities to the current epidemic with respect to populations and strategies?**

- The panel recommended an internal review of CDC HIV prevention funding at the various organizational unit levels (CDC OD, Coordinating Center, Center, Division, Branch) and a review of historical information, and for DHAP to gain control over all available HIV prevention resources.
- The panel also emphasized the need for greater transparency in the planning process so external sources could learn where funds are being directed. In particular, the panel recommended a measure of the cost of delivering services to clients and to examine these efforts at the national level.
- Data on cost effectiveness can be used to report to Congress and OMB to provide information on the relative efficiency of CDC’s HIV prevention efforts relative to other investments of federal resources.
- The panel recommended that the economic reality be considered, including survival of CBOs and the cost of prevention that can be sustained over time.

6. **How appropriate is the relative mix of prevention efforts directed toward persons living with HIV and those not yet infected?**

- Programmatically, the panel stated that DHAP may want to focus on some key strategies for HIV prevention and evaluate them thoroughly. Examples of these would include increased efforts within prisons and other corrections facilities, mental health and substance abuse treatment providers, and supported housing.

7. **How appropriate are the substance and scope of DHAP’s strategic priorities relative to the Division’s mission?**

- The panel recommended developing the framework of “highly active HIV prevention” (HIHP) in order to articulate the need to scale up prevention efforts at the national, state, and local levels. A comprehensive framework would enable jurisdictions to better target and tailor their HIV prevention response to their local epidemics. Efforts can also be expended to increase understanding of HIV prevention, foster improved messaging and marketing, and provide more information on planning efforts.

8. **How clear and focused are DHAP’s strategic priorities, and have they been articulated and communicated adequately?**

- The panel recommended a higher level of policy leadership, beyond funding, to support strategies such as needle exchange programs (NEPs) and to ensure adequate support for existing and new initiatives.
- Prevention activities can also be supported by seeking synergies with other activities and other federal agencies, including testing expansion, screening, and linkage to care, and by treating HIV treatment as prevention.
9. How well do DHAP’s strategic priorities support 1) collaboration among HIV, STD, viral hepatitis, and tuberculosis programs and 2) integration of HIV, STD, viral hepatitis, and tuberculosis prevention services at the client level?

- A plan must include comprehensive program and policy alternatives that are prioritized and rely on synergy among the national, state and local levels; be adjusted as needed; and be based on the data collected.
- A model can be used to quantify the priority-setting process and the selection criteria, especially to determine the priority for activities for certain populations (transgendered) and to determine the impact of new strategies.
- The panel recommended that DHAP develop a formula for prioritizing activities based on the epidemic burden. The formula should include incidence and prevalence rates and use data from DHAP and other sources (e.g., foundations, national organizations).
- The panel requested that DHAP develop a more clearly articulated policy agenda along with an analysis of how policy changes might impact program effectiveness and, ultimately, the trajectory of the epidemic. At present, policy may include DHAP guidelines, reporting requirements, state and local laws, and policies that are outside of CDC’s purview. The panel emphasized the need for transparency, including at the Financial Management Office (FMO).
- Some barriers were cited by the panel, including delays in obtaining input from the chain of command, and the role of Coordinating Centers within CDC, and the Office of the Director and communications with Congress.

10. How well do DHAP’s strategic priorities support reduction of health disparities?

- The panel did not have an explicit conversation about this question, but the theme of health disparities was woven throughout many of the conversations. However, an underpinning of the panel’s discussion was the need to address HIV/AIDS disparities and ensure that DHAP planning and prioritization processes resulted in better targeting of resources to address disparities based on race, ethnicity, and sexual orientation.

11. What are the principal gaps in DHAP’s strategic priorities?

- The Panel emphasized the need for a National HIV Prevention Plan—likely to be part of the National HIV/AIDS Strategy—in which CDC can play a pivotal role for the federal government, providing a national public health vision, leading by example the rest of HHS and the Executive Branch, including the White House. The panel members indicated that a leadership model was required to include input from within DHAP and other governmental and non-governmental entities that have valuable input on the development of this National Plan. DHAP can provide leadership in this process and encourage participation from frontline organizations.
- The panel indicated that it is DHAP’s role to lead the HHS HIV prevention effort, collaborate with other federal agencies, both within HHS and with other departments. DHAP’s unique role is to prevent as many HIV infections as possible, considering all
available opportunities, and report annually on the state of the epidemic so that future strategies will be based on the likely trajectory of the epidemic.

Results Monitoring

12. To what extent is DHAP’s national monitoring and evaluation plan explicit and technically valid?

- Monitoring efforts can begin with determining a standard set of questions to be addressed, including input from grantees, and one standardized system that can incorporate all data collected, ensure there is not an overwhelming amount of data, and consider unintended consequences. In developing this centralized system, the lessons learned of the Program Evaluation and Monitoring System can be used. The process to develop and revise the questions should be flexible to respond to the reality of government.

13. To what extent are the data sources included in the plan adequate and appropriate, and what other data sources should be included?

- The panel recommended the standardization of data collection efforts across all federally funded testing initiatives, uniformity of data reporting and coding requirements among jurisdictions and the validation of data. The social impact of the testing activities within the various populations can also be explored.
- Data collection efforts can go beyond CDC to include other HHS agencies that can report standardized demographic information on populations.

14. How adequate and appropriate are the outcome and impact measures described in the plan in terms of their ability to assess DHAP’s programs and their public health impact?

- The panel raised the issue of who would have ultimate responsibility for monitoring and accountability, what data should be collected, and what would be measured. The panel stressed the use of various types of data, including core surveillance and grantee evaluation data, and lessons learned and the need to adequately fund the data collection efforts and meta-evaluation.

15. What are the strengths and weaknesses of the plan and what are your recommendations for improving it?

The panel concurred with the following statements:

- “To achieve optimal public health impact, the appropriate combination of evidence-based HIV prevention strategies must achieve sufficient coverage, intensity, and duration.”

---

• Combination HIV Prevention: “Effective HIV prevention involves the simultaneous use of diverse and integrated prevention strategies—programs that help individuals prevent transmission, broader-based initiatives that alter the norms and behaviors of social groups, and increased access to tools that reduce the biological likelihood of transmission.”

• Analogy to HIV Treatment: “The parallels between HIV prevention and treatment are striking. Like antiretroviral therapy, HIV prevention is life-long, and its impact must be continually monitored and the prescribed regimens revised as circumstances and needs change. Just as a single pill cannot eradicate HIV, one-shot prevention efforts will not achieve the magnitude or sustainability of behavior change required to alter the epidemic’s course…Like treatment, effective HIV prevention requires a combination of strategies.”

The panel made the following issue-specific recommendations:

• DHAP should continue conversations around needle exchange and preparation for the possible lifting of the ban on the use of federal funds.
• DHAP’s sero-sorting position statement is an opportunity to identify and respond to a evolving issue in the future course of the epidemic.

B. SURVEILLANCE

The Surveillance Panel reviewed written materials and heard presentations from DHAP personnel on the various components of the surveillance system and explored the sufficiency of CDC’s efforts in this area. The panel also considered the extent to which the data gathered through core and other surveillance activities are used to inform the decision-making process internally and externally and the interaction of program and surveillance.

Topics addressed:

• HIV case surveillance
• Incidence surveillance
• Drug resistance surveillance
• Behavioral surveillance
• Clinical surveillance

The Surveillance Panel recognized that DHAP and the jurisdictions are at a turning point in the ability to monitor, characterize, and impact the epidemic: for the first time in the history of the epidemic there is a national confidential name-based HIV reporting system; DHAP, in conjunction with the jurisdictions, has developed a rigorous Technical Guidance document that details required activities and best-practices; universal process and outcome performance standards have been published and are beginning to be monitored; training on the Technical Guidance and performance standards has occurred and is ongoing; and by the end of 2009 all jurisdictions will have implemented a new data management system that will allow jurisdictions and CDC to analyze surveillance data more sensitively for quality assurance and monitoring purposes as well as to support the increasing volume of electronic reporting technologies. In 2008, two other significant developments related to HIV surveillance were realized by CDC: a revised national HIV incidence...
The current system, which includes core surveillance as well as HIV incidence, resistance, behavioral and clinical surveillance components, also has many challenges which are discussed in the following sections.

1. **To what extent are the surveillance methods and resulting data of high scientific quality?**

   **Core Surveillance**

   The panel members concurred that the Core Surveillance methods are robust and the system is becoming stronger with nationwide implementation of confidential name-based HIV reporting, documented technical guidance, and standard evaluation criteria. The quality of data from core surveillance systems, however, vary from jurisdiction to jurisdiction depending on the extent to which sites have implemented the required activities such as birth and death ascertainment activities, Routine Interstate Duplicate Review (RIDR), laboratory reporting (including CD4 counts and viral loads), document-based surveillance, and name-based reporting. As more people are living with HIV and living longer, and as the surveillance system continues to evolve in ways that can facilitate monitoring and identification of prevention opportunities along the spectrum of disease, the demands on the fundamental “core” system are expected to continue to increase. The panelists identified the following issues that impact the system’s ability to produce data of high scientific quality:

   - There is a need to strengthen the core surveillance infrastructure, potentially as a priority over other ancillary surveillance activities, so that sites are able to conduct the required activities and meet the performance standards.
   - The increasing volume of laboratory reports and other electronic reports is a significant challenge to the system. Receiving and managing electronic data require sites to adopt major data processing capabilities. More robust standard data matching and processing tools and expertise are needed in many areas.
   - Transition to the new data management system (eHARS) is not yet complete at the jurisdiction level or within CDC’s data management and analysis processes. In addition, important corrections are still needed in the data system, such as for HIV-2 cases to be recorded and the calculation of variables for perinatal exposure cases.
   - Surveillance programs and data management systems need to be prepared to incorporate the evolving testing technologies in data collection, management, and dissemination activities. Such advances may also necessitate timely changes to case definitions.
   - Participants noted the need for an updated case residency consultation, reconsideration of the hierarchical approach to classification of risk, and guidance related to implementing surveillance of acute infections.
   - Panelists observed that gaps in reporting from federal programs, such as Veteran’s Health Administration facilities, affect many areas. Intervention is needed by CDC to ensure that programs administered by federal counterparts are cooperative with national disease reporting standards.
   - Capacity for data analysis and dissemination has challenges locally and within CDC (see Question 3: Constituent Needs and Question 5: Resources and Capacity).
**HIV Incidence Surveillance**

HIV Incidence Surveillance is still a young surveillance system and its overall functioning and quality has yet to be assessed. The system is complicated to implement, and panelists expressed some reservations about the scientific quality of the incidence estimation methodology given that not all labs participate, the inaccuracies inherent in Testing Treatment History (TTH) information, and whether the fundamental assumptions of the model will continue to be appropriate over time with changes in testing patterns and technologies. In addition, the extent to which the incidence estimates are representative of the nation will be better understood once there is a complete national HIV case surveillance dataset. Other specific observations and recommendations:

- Panelists were cautious about the use of data from the current system as the sole marker for national prevention goals. Locally, estimates do not appear sufficiently stable at this time to inform prevention activities in most jurisdictions.
- Panelists recognized the importance of measuring incident infections as a part of understanding the epidemic. Towards that end, some recommended that CDC work with FDA and manufacturers for faster approval of 4th generation HIV diagnostic tests and new tests for incident infections that could be conducted directly on specimens by the laboratory/testing entity avoiding the need to secure remnant specimens.
- In order to evaluate the strength of data used in the current estimation model, CDC is currently funding a special project to assess the accuracy of TTH data. Panelists suggested that CDC consider whether data collected through core surveillance nationwide might be able to assist with this validation, such as comparing self-reported testing information from Counseling/Testing programs to surveillance.
- Some panelists also recommended that incidence data, in particular infections identified in the acute phase, represent an opportunity to intervene and interrupt transmission. As CDC moves forward with the development of approaches to monitor incident infections, panelists were supportive of exploring surveillance/prevention collaborations to identify clusters and attempt to stop transmission. The group supported the approach that CDC is advancing through the “STOP” Project.

**Drug Resistance Surveillance**

Panelists recognized the potential value in monitoring medication-resistant strains of HIV nationwide. The current system, however, is in the early stages of development and is transitioning from an approach that requires acquisition of remnant specimens to a more standard laboratory reporting surveillance method. Panelists noted that this activity is logistically and scientifically complicated, and additional guidance is needed to ensure that the resulting data are appropriately managed and interpreted. The system has not yet been evaluated.

- Guidance is needed for jurisdictions to assess if they have sufficient coverage of resistance testing in clinical practice to discontinue the cumbersome process of obtaining remnant specimens that meet the rigorous handling requirements to be tested.
Establishing reporting of results from laboratories is challenging, even for sites with permissive regulations and advanced technical capabilities. The capacity of laboratories to provide the data electronically is variable.

Panelists identified many outstanding issues related to analysis and use of data, including the appropriate timeframe for analyzing results (within three months of diagnosis versus one year); the appropriate use of data for identifying clusters and informing prevention or clinical activities; and submission of genotype results to public-access scientific databanks such as GenBank. Input from sites and field experts are needed to inform additional guidance and technical assistance to ensure appropriate and meaningful use of data from this system.

**Behavioral Surveillance**

The panelists concluded that the National HIV Behavioral Surveillance (NHBS) is a strong project with good collaboration and analysis. The panelists had the following considerations related to ensuring the validity and utility of NHBS data:

- Eligibility for funding is based on the 2002 AIDS case data; panelists recommended considering if the project is appropriately representative now that universal HIV reporting has been implemented and more recent data are available.
- The strengths and weaknesses of respondent-driven sampling (RDS) should be assessed.
- Panelists recommended that CDC consider more flexible models for the cycles or location activity (e.g., consider single survey in some areas that have relatively homogeneous populations; consider expanding activities to lower morbidity areas to ensure representation and to gather information on non-urban populations, perhaps using a regional model to achieve sufficient sample size).
- Reviewers encourage CDC to explore opportunities to incorporate behavioral surveillance activities (not necessarily using the NHBS model) into TB, hepatitis, and STD program activities as a means of adding to the portfolio of monitoring risk behaviors. Some panelists also felt that there was an opportunity to conduct behavioral surveillance focused on acute HIV infection (AHI). If nucleic acid amplification testing (NAAT) and surveillance for clinical syndromes consistent with AHI were to become more widespread, there may be an opportunity to interview a sizable number of persons with AHI to better understand their risk behaviors and “thinking” (knowledge, beliefs and attitudes) at the approximate time they were infected.

**Clinical Surveillance**

The Medical Monitoring Project (MMP) is important as the only present-day study that attempts to assess a representative sample of HIV-infected persons in care to understand their care utilization, clinical characteristics, and risk behaviors. The panel agreed that 2009 is a critical year for MMP, which still has not been fully implemented after five years of funding. The panel recommended that CDC evaluate the program to identify roadblocks (e.g. OMB delays, stipends for and randomization of providers, capacity and resources to implement, real time sampling); determine if these roadblocks are adequately addressed; answer questions; and
establish specific performance indicators. After completion of 2009 data collection, panelists recommended that the feasibility of the methodology be reviewed.

In addition, some panel members felt that some outcomes being monitored by the MMP (e.g., continuity of care) might be more easily monitored through measuring regularity of getting viral load tests and CD4 counts as part of core surveillance. Where the MMP is in place, comparison of outcomes using surveillance and the MMP should be done.

2. **To what extent are the objectives of each DHAP surveillance system adequately described in, clearly linked to and consistent with the Division’s mission, goals, and priorities?**

The materials provided to the reviewers did not specifically articulate how the objectives of each of the presented surveillance activities are linked to specific Division goals and priorities. However, the panelists did consider the stated the HIV Incidence and Case Surveillance Branch (HICSB) and Behavioral and Clinical Surveillance Branch (BCSB) goals of implementing surveillance and research activities that guide public health action at federal, state, and local levels. Overall, jurisdictions likely do not understand how their activities are linked to specific DHAP goals and priorities. With surveillance data essential to monitoring many goals established through various national strategic planning processes, such as CDC’s HIV Prevention Strategic Plan and the expected development of a National AIDS Strategy, it would be important for DHAP to ensure that surveillance jurisdictions understand how the DHAP goals tie into larger national goals and how the local level activities support those goals. In addition, the panelists had the following observations and recommendations:

- As noted in the summary, the case surveillance system is getting stronger with the realization of universal HIV reporting in 2008 and the implementation of common standards for the completeness, timeliness, and accuracy of jurisdiction-level surveillance systems. Given the strengthening foundation and potential capabilities of surveillance, CDC should re-examine the strengths of and demands on the surveillance system and reconsider what surveillance should be measuring and doing as well as assess the resources that are needed to support those activities as a partner in HIV prevention.

- The panelists were vigorously supportive of the inclusion of milestones in CDC’s *Extended Plan* that are specific to strengthening the capacity nationwide to monitor the epidemic. A robust surveillance system is essential to supporting sound programmatic decisions nationally and locally.

- A stated common goal of CDC’s surveillance branches is to conduct activities that will guide public health action at the federal, state, and local levels. Over the course of the review, the panel discussed several challenges for surveillance to action:
  - Cooperative agreements with the jurisdictions generally support data collection and not data analysis. The *Epidemiologic Capacity Building Technical Assistance* funding is an example of dedicated analysis effort and information sharing available to some areas, supported by both Prevention and Surveillance resources, that could be further developed to help ensure that surveillance data are analyzed and effectively incorporated into local planning and evaluation processes.
Some surveillance activities are not currently producing data that are able to be used at the local level (see details in state/city/jurisdiction constituency issues identified in Question 3).

Stronger tools and approaches are needed to help jurisdictions ensure that surveillance data and information from other studies and evaluation activities are utilized in a way that is most likely to impact the epidemic.

The newly released HIV Partner Services guidance recognizes the important prevention opportunities that can be realized when surveillance programs collaborate with prevention programs. Panel members supported CDC’s development of this guidance and noted the ongoing need for CDC to incorporate rigorous security and confidentiality requirements in cooperative agreements across the agency’s divisions.

3. **To what extent do the surveillance systems and products adequately meet the needs of CDC’s constituencies?**

The panel at different points in the review discussed several constituencies of DHAP surveillance systems and products. In particular, the participants considered how surveillance activities impact programs and processes within CDC, jurisdiction-level prevention and surveillance programs, HIV Partner Services programs, and HRSA Ryan White CARE Act programs. An overarching recommendation from the panelists, also articulated in the response to Question 2, was for CDC to look outward to reconsider the scope of surveillance activities and assess the increasing demands on the surveillance system.

**CDC Prevention and Epidemiology programs as constituents**

- The extent to which CDC surveillance personnel are incorporated into the CDC prevention and evaluation planning processes was not clear to the reviewers. Given there are particular strengths and weaknesses of the surveillance system activities and the resulting data, surveillance expertise would be valuable both to interpret surveillance results and to guide decisions being made within CDC for developing prevention strategies, prioritizing interventions, developing campaigns, and establishing evaluation criteria or indicators.
- The panel participants identified some instances of gaps and other instances of duplication across CDC divisions and DHAP’s branch activities where data that are already being collected in one activity might be useful for another and might help support DHAP’s evaluation of progress towards attaining goals. In particular, there may be a benefit in evaluating the data collected through Core Surveillance, Medical Monitoring Project (MMP), National HIV Behavioral Surveillance (NHBS), Enhanced Perinatal Surveillance (EPS), Fetal and Infant Mortality Review (FIMR), and STD, TB, and other infectious disease surveillance activities to identify any unnecessary redundancy as well as additional available data that can help measure progress towards the Division’s goals overall.
States/cities/jurisdictions as constituents

- Although most CDC surveillance activities are intended to provide locally useful data for monitoring the epidemic as well as guiding and evaluating prevention efforts, the benefit to local sites is often not fully realized. For example:
  - Core Surveillance appears to be funded primarily for data collection and management activities, but not for local data analysis. DHAP should provide adequate funding and/or technical assistance to ensure that data are analyzed to inform local program needs.
  - Some jurisdictions funded for HIV Incidence Surveillance remain unclear about how best to use the data to inform program or if that system will produce sufficiently stable estimates to be meaningful locally.
  - Currently many jurisdictions lack the capacity to analyze resistance sequence data. DHAP should provide adequate funding and/or technical assistance to ensure that data are analyzed to inform local program needs as there is no consensus from CDC on analysis criteria. (CDC personnel noted during the discussions that guidance and technical assistance was anticipated later this year).
  - Some areas relay that behavioral surveillance data are inadequate for genuine evaluation of local prevention efforts.
  - The respondent sample size for many MMP sites is small and could limit locally useful data unless high patient participation rates are achieved by allowing and/or developing a more successful sampling methodology, such as Real Time Sampling. Data has thus far not been returned in a timely manner for analysis.
  - Lower morbidity areas generally do not qualify for “supplemental” surveillance activities, resulting in a less than complete characterization of the epidemic and of the behaviors of persons in those areas and nationally.
  - Jurisdictions are eager to have additional information to inform prevention. CDC’s recent back-calculation of case surveillance data provided rich national data complementing the new incidence estimation methodology and allowed for the estimation of transmission and unknown status. Panelists encouraged that technical assistance be available if such approaches could be applied locally.

- In order to assist surveillance programs with the provision of data to local prevention and care programs, CDC developed technical guidance and analysis programs for jurisdictions to produce a local Epidemiologic Profile document. While a very rich resource, many jurisdictions have found the recommended document cumbersome both to produce and for local planning bodies to use. The panelists recommended that CDC partner with the jurisdictions’ surveillance and prevention programs to assess how the Profile is (or is not) used and reconsider best practices for ensuring the appropriate incorporation of surveillance and other data in local planning processes. Smaller, more frequently produced Profiles may be more responsive to planning group needs. Panelists also noted that there is little funding to specifically support the development of the profiles.

- The use of GIS mapping to better correlate HIV infection with other socio-economic and geographic characteristics may provide information useful for planning; a recommendation was made for CDC to consider supporting the technical capacity for GIS mapping and small-area analysis of HIV by socio-economic status (e.g., percentage of persons living below poverty in the “neighborhood of residence”).

External Peer Review
Findings and Recommendations
November 1, 2009
Page 34
The panel acknowledged the Division’s production of several summary products that accompanied the release of the incidence estimate in 2008 that areas found particularly helpful and encouraged CDC to consider developing similar materials to accompany other routine and non-routine surveillance reports. Often local jurisdiction staff, even those fairly knowledgeable, find that some CDC surveillance reports currently are not at all easy to understand.

**Ryan White CARE Act programs as constituents (federal and local programs)**

- HRSA programs are major “consumers” of surveillance data—national funding allocations presume an equitable and high-performing surveillance system across the country. Also, local care programs rely on surveillance programs for accurate, clear, simple summary data products in order to guide allocations, planning, and grant applications. Appropriate determination of unmet need for HIV primary medical care requires timely and complete local surveillance systems with comprehensive laboratory reporting and strong analysis capacity. Overall, panelists reiterated the importance of a strong collaborative relationship between HRSA and CDC, as surveillance capacity has a significant impact on HRSA programs both locally and nationally. Reviewers also noted the following:
  - With confidential name-based reporting now implemented in all jurisdictions, panelists urge CDC to reconsider its recommendation to HRSA on how best to utilize HIV morbidity data for HRSA funding, specifically noting that CDC evaluate the feasibility of switching from residence at diagnosis to most current residence for assigning state “ownership” of cases.
  - Grant applications to HRSA for the various Ryan White program “parts” require extensive local analysis of surveillance data. Reviewers requested that CDC work with HRSA to specify and consolidate the type and source of information needed for federal funding applications and progress reports.
  - Panelists also identified opportunities for collaboration and consolidation around the data collected to monitor and evaluate Ryan White programs. With HRSA’s development of a code-based client-level data system (a type of system just abandoned by CDC), Ryan White programs are required to collect and record information that may already have been collected and recorded in the de-duplicated surveillance system. While not advocating for a merging of the two systems, panelists urged the agencies to consider the efficiencies that could be gained with greater coordination around data needs.

**Partner Services programs as constituents**

- The current surveillance system functions as a look-back system that is not particularly timely for intervention. In the panel’s discussions related to HIV incidence surveillance, participants noted the potential increasing importance of a more timely surveillance system with the opportunities to interrupt transmission among reported acute infections, specifically noting that CDC evaluate the feasibility of switching from residence at diagnosis to most current residence for assigning state “ownership” of cases. As technologies to detect acute and recent infections evolve, the importance of surveillance working closely with Partner Services programs could be critical. Panelists encouraged that...
CDC consider the potential role of surveillance as a part of the prevention portfolio and the resources that would be needed for the system to serve in this capacity.

4. **To what extent are the surveillance systems adequately evaluated and the results effectively disseminated? To what extent are the data used by prevention activities for program development and evaluation purposes?**

**Evaluation of surveillance systems and dissemination of results**

- For **Core Surveillance**, HICSB has made a significant investment in preparing jurisdictions for the implementation of rigorous, ongoing evaluation activities through the development of process and outcome standards, publication of standards in the *Technical Guidance* and articles, ongoing training, and incorporation of key standards in grant applications and progress reports. In addition, by the end of 2009, HICSB will have completed the deployment of the data management system, programs, and technical guidance needed to implement national evaluation activities. The plan appears rigorous. Participants noted that HIV surveillance seems to be one of the most comprehensive surveillance systems existing for any condition. While CDC has established performance standards, a thorough evaluation of the system has not yet been done nationally or locally in a uniform way. Preliminary results of the informal reporting by the sites of required process and outcome standards (from the 2007 APR and 2008 APR) have, to date, not been disseminated. As a result, the panelists could not definitively speak to the quality of the data. Additional observations:
  - Panelists asserted that some components of the evaluation plan are very complicated and may need to be reconsidered in light of what is practical in a non-research setting and what is most important or meaningful for improving the system given the available resources.
  - With laboratory reporting becoming such a major component of the surveillance system, there might be a benefit to developing process standards that prompt jurisdictions to monitor and evaluate the laboratory-reporting component specifically. Although sites ultimately need to meet the outcome standards and CDC does not necessarily want to dictate how sites need to achieve those standards, additional guidance and recommended standards would appear to be helpful.
  - Feedback to jurisdictions about how they compare to other programs with the implementation and achievement of standards would be useful.

- For **HIV Incidence Surveillance**, performance standards are defined, but some appear unattainable in the current model of incidence surveillance that depends upon the availability of remnant specimens. The panelists also noted that incidence data are part of several national prevention monitoring and evaluation goals, but question if the system is or will be sufficiently robust to provide those measurements alone.

- No formal evaluation has been conducted to date for the **Variant, Atypical, and Resistant HIV Surveillance (VARHS)** program. This is a developing system that is complicated and achievement of the defined outcome standard will be difficult, especially as long as sites rely on testing of remnant specimens.
• The panel recommended that CDC evaluate **National HIV Behavioral Surveillance (NHBS)** once two complete cycles have been completed to assess the strengths and weaknesses of respondent-driven sampling (RDS) and consider a more flexible model for the cycles or location activity (e.g., consider single survey in some areas). For example, in areas whose epidemic is almost entirely MSM, it may not make sense to conduct the IDU or HET cycles.

• The panelists strongly recommended the CDC evaluate the **Medical Monitoring Project (MMP)** in early 2010 to assess if the protocol can be implemented as designed and deliver the intended results. And if not, that its methods be changed to be more easily meet the goals of collecting representative clinical surveillance data. If the goals are assessed to be unachievable, then serious consideration should be given to either eliminate MMP or redesign it with a more workable methodology that produces useable data.

**Application of surveillance data for prevention program development and evaluation**

• The panel discussed the need for tools to ensure that surveillance data are utilized appropriately to align resources and interventions for the areas of greatest burden or areas, populations, or groups that are disproportionately affected, within CDC and at the jurisdiction-level. The materials provided for the review cited a resource allocation model under development to assist with optimal allocation of funds. CDC personnel clarified that such a model is not currently available for jurisdiction-level planning processes.

5. **To what extent does DHAP have adequate capacity and sufficient resources devoted to surveillance, consistent with the Division’s mission, goals, and priorities?**

Overall the panel members concurred that DHAP does not currently have adequate capacity or resources devoted to core surveillance activities, which not only have dramatically increased in volume and complexity, but also serve as the foundation upon which prevention and care programs are based. As described in the responses to the other sections, the reviewers urge CDC to consider the demands on and the deliverables of the surveillance system activities, present and future.

• The reviewers recognized the value of each of the activities in the current surveillance portfolio but asserted that strengthening the national HIV reporting system (Core Surveillance) and ensuring rigorous national and local analysis capacity should be priority activities when resources are limited.

• The method of determining allocations across surveillance programs was not well understood by the reviewers. The panel recommends assessing funding levels across jurisdictions to ensure appropriate parity.

• CDC staffing and capacity did not seem at all sufficient to ensure meaningful support to or monitoring of sites. Some CDC epidemiologists providing support are new to the Branch and do not have enough familiarity with the complexities and intricacies of HIV surveillance activities. Provision of in-depth technical assistance and trainings—such as the beneficial trainings and meetings related to incidence estimation—is putting a strain on CDC program personnel resources. Lower morbidity areas in particular may require additional technical assistance for data analysis that CDC staff may be unable to provide.
• The needs for technical assistance are great and continue to increase, whether it be ensuring the effective use of surveillance data for programs; implementing HIV Partner Services collaborations; transitioning data management systems to more complicated SQL platforms; implementing and managing electronic reporting from laboratories, facilities, and other reporting systems; implementing, managing, and analyzing genotype/phenotype data in particular; changing the surveillance system with advances in testing technologies and interventions; or ensuring nation-wide achievement of performance standards.

• Comprehensive laboratory reporting in all jurisdictions demands technical expertise for establishing and maintaining rigorous local systems, but the benefits are significant locally and nationally. Such reporting offers complete and timely data for: monitoring trends in newly diagnosed HIV infection and prevalence of HIV infections; entry, continuity, and retention in care; and timely referral of cases for partner services and linkage to care and prevention services.

• Information Technology resources within CDC do not seem sufficient as evidenced by long-standing corrections needed for eHARS (e.g. perinatal, HIV-2, others). Greater coordination of IT solutions is needed across HIV surveillance components, prevention components, and perhaps even the prevention and surveillance of other diseases, such as STD, hepatitis, and TB.

6. **To what extent is the mix and balance of surveillance activities relevant to the current epidemic?**

While the panelists did not specifically address the question of the “mix and balance” of current surveillance activities, over the course of the review various recommendations emerged that speak to this issue:

• CDC’s efforts to support rigorous, complete, core HIV surveillance systems at the jurisdiction level is the fundamental activity required to ensuring appropriately balanced and representative surveillance activities.

• Over the past several years, CDC has moved towards incorporating incidence and resistance surveillance activities into the “core” surveillance processes and systems. With the anticipated advances in testing technologies and clinical practices, incorporation of these components into “core” activities seems reasonable but should be evaluated as the incidence and resistance systems mature.

• Panelists recognized the need for and value of behavioral and clinical monitoring components as a part of national HIV surveillance efforts, but asserted that these activities should not supplant core surveillance infrastructure. It may be that the core surveillance system, which now includes longitudinal clinical data, may be able to provide some of the information needed for clinical surveillance. Behavioral data may also be able to be appropriately monitored through more effective coordination with other prevention and disease surveillance programs.
7. **What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the program?**

Many recommendations for changes, enhancements, de-emphasis, future directions and priorities are addressed in the preceding questions of the Surveillance Panel Summary as well as in the brief panel summary in section IIB of the report. The recommendations not already addressed primarily relate to the need for greater efficiencies and collaboration within DHAP and across CDC programs:

- Closer integration and collaboration between the prevention, research, evaluation, and surveillance programs is needed to eliminate unnecessary duplication of efforts and to maximize the use of available data to advance prevention efforts.
- Greater coordination between DHAP prevention and surveillance programs could help to ensure jurisdiction-level collaboration with key shared activities and performance measures.
- Across CDC’s disease surveillance programs, crosscutting issues such as poor reporting from the Veteran’s Health Administration facilities might be more effectively addressed as a coordinated effort.
- The new HIV Partner Services guidelines represent a critical milestone in recognizing the valuable prevention opportunities that can occur when surveillance supports public health action. Many barriers to implementation remain, however. While technical challenges exist, the greater challenge will likely prove to be in the navigation of organizational “cultures” and approaches. The extent to which CDC actively holds all programs and grantees accountable to similar security and confidentiality standards will directly impact how quickly programs move towards collaboration and integration of shared functions.

C. **BIOMEDICAL INTERVENTIONS, DIAGNOSTICS, LABORATORY, AND HEALTH SERVICES RESEARCH**

**Topics to be addressed:**

- Biomedical interventions
- Diagnostics and testing
- Laboratory research
- Health services research (including cost-effectiveness)
- Research-to-program translation and dissemination

The Biomedical Panel had an opportunity to review the current status of research conducted on biomedical interventions, such as the development of new assays, surveillance of acute HIV infection, and the use of various research methodologies. The Panel was presented information on current research conducted by the various branches, both internally and externally, and reviewed the data gathered from research and was able to question how the priorities for research are determined within DHAP and possible synergies with other CDC components.
1. To what extent are the biomedical, laboratory, and health services research projects and resulting data of high scientific quality?

- The panel was clear that they believed the projects and resulting data were of the highest scientific quality. They affirmed that the investigators were also of the highest quality.

2. To what extent are the objectives of each biomedical, laboratory, and health services research project adequately described and clearly linked to and consistent with the Division mission, goals, and priorities?

- The panel noted DHAP’s unique role was in translational research, helping to disseminate the findings of clinical trials into public health practice.
- The panel discussed that the process for setting priorities, and the criteria used, including level of effort and research required was unclear. This included the following specific domains:
  - Pre-Exposure Prophylaxis (PrEP), microbicides, vaccine research
  - Diagnostics
  - Activities performed in consultation with other DHAP branches and external partners
  - Resistance testing (done in collaboration with industry)
- The panel questioned the process by which Branches determine what activities they carry out and who makes the final decision. Whereas priorities are determined at the Division level, branch chiefs can determine if the activities will be carried out and these may or may not match the Division level priorities.
- The panel questioned whether some legacy programs could be reprogrammed to other more effective initiatives.
- The panel discussed whether DHAP’s goals needed to be expanded so that CDC can be more agile and flexible in responding to the epidemic. They discussed the role of the CDC Washington, D.C. Office.
- There was discussion between allowing the CDC to conduct investigator-driven research versus selecting research based on cost effectiveness.
- The panel discussed CDC’s role in the development of diagnostcs and research on incident and prevalent infections. Though this research has been historical and informative, it is not always unique to CDC and is occasionally investigator driven.
- The panel discussed CDC’s role in finding diagnostics to determine incidence, which will be helpful in determining program effectiveness.
- The panel felt that early detection is secondary to primary prevention, but clearly acknowledged that incidence data are important to target the work to the need.
- The panel discussed both the challenges and occasional necessity of combining behavioral and biomedical intervention development. They recognized that behavioral and biomedical research appears to occur in separate tracts and that little effectiveness research exists that studies the impact of combining behavioral with biomedical interventions. They observed that CDC would be ideally poised to conduct such research.
• The panel recommended the development of more innovative study designs, and better integration of behavioral and biomedical interventions as appropriate.

3. **To what extent do the biomedical, laboratory, and health services research activities adequately meet the needs of CDC’s constituencies?**

• As discussed above, the panel observed a poor correlation between the prioritization of research activities and broader prioritization processes within DHAP.
• The panel discussed the significant cultural and morbidity differences between white and black MSM and questioned whether or not adequate research had been conducted that took into account these differences.
• The panel questioned whether or not research has adequately addressed women who are infected while pregnant or how pregnant women who are infected became pregnant.
• Again, in order to better align research with DHAP priorities and goals including prioritized populations, the panel recommended establishing both an internal and an external scientific review panel (or process for periodic review) to assess existing and future projects so that only programs that are aligned with the mission and goals of DHAP are funded and implemented.

4. **To what extent are the biomedical, laboratory, and health services research products adequately evaluated and the results effectively disseminated?**

• The panel questioned how data is validated and how research models can be applied to the real world.
• The panel questioned how data are disseminated to decision makers. Though this is commonly done via published papers or Morbidity and Mortality Weekly Reports (MMWRs), the panel recognized that as a public health agency, this was not always the most rapid of mechanisms by which data could be shared. The recent HIV incidence figures were discussed as an example.
• The panel noted that CDC could do more to strengthen the communication of CDC-approved recommendations and guidelines.
• The panel questioned how the implementation of CDC guidelines is evaluated once they are released to the public. The panel noted that releasing guidelines is not enough to effectively disseminate new information. The CDC needs to also evaluate whether their recommendations are being carried out, and if they aren’t, what societal or legal factors need to be addressed or changed first to ease the implementation of the guidelines. In addition, the panel felt that guidelines need to be evaluated to determine whether they are realistic given the current health system infrastructure.
• The panel recommended that DHAP review its process for sharing data and guidelines to assure that it meets the needs of its constituents.
5. To what extent does DHAP have adequate capacity and sufficient resources devoted to biomedical, laboratory, and health services research consistent with the Division’s mission, goals and priorities?

- The panel discussed the impact of other entities, most importantly, the Global AIDS Program (GAP), on staffing levels. It was clear that many excellent DHAP staff had relocated to GAP, draining DHAP of personnel resources.
  - Specifically, the laboratory branch has lost several key staff to GAP and as a result have lost some capacity to carry out branch functions.
- The panel discussed the utility of cross-branch workgroups. The HIV Testing in Medical Settings workgroup was noted as effective in coordinating efforts across multiple branches.
- The panel questioned the prioritization of some biomedical interventions including PrEP, microbicides, circumcision, and vaccines. The panel recognized the CDC’s scientific contribution to these fields, but questioned whether there might be opportunity for greater collaboration with other partners including GAP, industry, and the National Institutes of Health (NIH).
- The panel discussed the importance of health services and cost-effectiveness research in the CDC scientific portfolio and the relative lack of prioritization these areas seem to be given. They discussed the few staff devoted to this type of research.
- The panel recommended that the DHAP Laboratory Branch and the GAP laboratory engage in more extensive collaborative activities in order to increase efficiencies and avoid duplication.
- The panel suggested DHAP explore expanding their health services and cost-effectiveness research portfolios by bringing in additional scientists and experts in these fields.

6. Are the Laboratory Branch’s diagnostics reference functions appropriate in scope, consistent with DHAP’s mission and goals, and adequately staffed?

- The panel noted the importance of the Laboratory Branch’s role in developing diagnostic assays for monitoring acute and recent HIV infection and confirming HIV infection.
- The panel discussed the need to develop an assay to detect non-clade B infections, which have been surging lately.
- The panel indicated that DHAP must be flexible enough to address changing diagnostic demands and that the research budget for biomedical interventions is not sufficient.
- The panel recommended that the Laboratory Branch continue to play a role in developing diagnostic assays and that this should be done in discussion with other federal agencies and industry that may be doing the same.
- The panel recommended that the Branch continue to serve as a reference laboratory.
- The panel recommended that DHAP engage external partners in an ongoing basis to ensure that they remain vigilant to the trajectory of diagnostic research.
7. Do DHAP’s biomedical, laboratory, and health services research activities reflect the appropriate mix of basic and applied research, and to what extent is the mix and balance of activities relevant to the current epidemic?

- As discussed previously, the panel observed an occasional disconnect between the research portfolio and DHAPs broader priorities. In addition, it was not clear how these broader priorities helped to inform the research agenda.

8. To what extent does the biomedical, laboratory, and health services research portfolio adequately advance the current state of science?

- The panel was clear that they believed the projects and resulting data was of the highest scientific quality. They affirmed that the investigators were also of the highest quality.
- The panel noted DHAP’s unique role was in translational research, helping to disseminate the findings of clinical trials into public health practice.
- The panel discussed the important role of the Laboratory Branch in conducting animal model research because it is a niche no one else can currently fill.
- The panel emphasized the importance of matching the scientific agenda with the current state of the epidemic.

9. What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the biomedical, laboratory, and health services research programs?

- The panel clearly recommended a review of the scientific portfolio as it relates to the priorities and goals of DHAP and the current state of the HIV epidemic as reflected in surveillance, programmatic, health services, and cost-effectiveness research.
  - The panel suggested that this review be recurrent, or a process, to allow for re-evaluation of legacy projects and ongoing research.
  - The panel suggested that the review take into account research being performed by external partners including GAP, industry, and NIH.
- The panel reiterated its recommendation that DHAP collaborate more with GAP, industry, and with NIH to find synergies.

D. **Behavioral, Social, and Structural Interventions Research**

The Behavioral Panel was able to review information on the current status of behavioral and structural intervention research, the different types of research the CDC carries out, and the interaction of expressed need for new and innovative behavioral interventions with the programs being implemented at the national, state, and local levels. The panel also reviewed the scientific quality and appropriateness of research being conducted and the process for determining the subject and scope of research being conducted.

**Topics to be addressed:**
• Behavioral, social, and structural interventions
• Communications and social marketing research
• Operational research (including cost-effectiveness)
• Linkage to care, retention in care, ART adherence
• Research-to-program translation and dissemination

1. To what extent is the behavioral research portfolio of high scientific quality?

• The panel questioned the definition of science and the purpose of DHAP’s activities, which is to reduce incidence and prevalence not improve science. Science should have an ultimate programmatic outcome in the areas of capacity, technical assistance, science of training, and quality improvement and assurance. The panel agreed that DHAP should focus on applied research and real world issues, but questioned whether their current resources allowed for this type of paradigm shift.
• The panel recommended an expanded definition of behaviors to also include organizations, individuals, and social groups.
• The panel questioned whether DHAP’s focus on populations and demographics of race, gender, and sexual orientation translates effectively into intervention designs.

2. To what extent are the objectives of the behavioral research portfolio adequately described, clearly linked to, and consistent with the Division’s mission, goals, and priorities?

• The panel emphasized that research efforts should reflect science and philosophy and engage in innovative methodologies and give more emphasis to practice-based research.
• The panel came to consensus that while it remains important to acknowledge the disparate impact of HIV on specific populations, institutionalizing the response by population group has not proven to be effective and has had some unintended consequences. In particular, attention has been shifted from the social and individual practices conferring vulnerability and influences that increase the risk of HIV transmission to compartmentalizing individuals based on race/ethnicity; sex/gender, which generally is not appropriate or effective for intervention.
• The panel recommended that DHAP engage exclusively in Phase 1 and Phase 4 research activities, as those are the ones that can be more completely carried out within DHAP’s existing structure, and the current research model is not adequate. The Capacity Building Branch, given support in the development of study design, can carry out some research.
• The panel questioned if a logic model for developing social marketing campaigns exists. For example, when questioning CDC staff about why one program is considered and another is not, there was no clear answer provided.
• The panel noted that the theoretical models that drive program development, implementation and evaluation do not reflect a unified conceptualization of behavior change. For instance, in three projects presented to a group that focused on increasing HIV testing, six different models were used.
• The panel questioned CDC’s focus on medication adherence and whether this was an appropriate topic for CDC’s prevention research portfolio. It was pointed out that other
federal agencies (National Institute of Mental Health, HRSA) may have asked CDC for assistance in dissemination of adherence interventions, and further information is needed to better understand the rationale for a focus on antiretroviral therapy (ART) adherence.

3. **To what extent do the behavioral research findings/products meet the needs of CDC’s constituencies and inform programmatic efforts?**

   - The panel recommended that research take into account the needs at the community level and bridge research to practice with community-centered models. The panel emphasized that in communities there is no demographic distinction of individuals and questioned the meaningfulness of research conducted along strict demographic lines to CBOs.
   - The panel recommended DHAP review the process for translating research findings into programs for implementation by CBOs. The analysis should include the cost of implementation and barriers commonly reported to implementation, including staff turnover at CBOs.
   - The panel encouraged CDC to work with health departments and CBOs in operational research to ensure that evidence-based and data-supported linkage to care strategies are used in conjunction with HIV testing. The goal is to make sure that persons newly diagnosed with HIV and persons not connected to care are linked and retained in care.

4. **To what extent are the prevention interventions and strategies within our research portfolio adequately evaluated (adequacy of research methods) and effectively disseminated?**

   - The panel discussed structural interventions and their role in the DHAP research agenda, which should come secondary to operational effectiveness research and is closer to DHAP’s role as an implementer of public health programs.

5. **To what extent does DHAP have adequate capacity and sufficient resources devoted to behavioral research, consistent with the Division’s mission, goals, and priorities, and consistent with the mission of our other federal partners?**

   - The panel recommended that DHAP work with the NIH to address research gaps and avoid duplication of effort, including knowledge about treatment and adherence, and it should be DHAP’s role to serve as conduit to health departments and communities.
   - The panel emphasized the need for collaboration among the research and program branches.

6. **To what extent are the strategies, and the mixture and balance of these strategies, within the behavioral research portfolio appropriate and relevant to the current epidemic (with respect to various strategies or tactics, various populations or risk groups, and individual, social, structural, or other risk determinants)?**

   - The panel recommended that research projects be done in collaboration with CBOs funded to implement programs and that DHAP’s approach to gathering best practices be more global.
The panel observed that currently DHAP’s operations research is focused on adaptation, effectiveness/replication studies, and improving Effective Behavioral Intervention (EBI) implementation. While these activities are appropriate, the panel recommended a redefinition of applied research in DHAP that maximizes opportunities to solve the real-world problems of dissemination and implementation. The adaptation process, for example, is not the subject of current research. The panel recommended that the research focus on the processes of a dissemination science that emphasizes scientific studies of the training procedures, end-user response to guidance, implementation strategies, contract manager effectiveness, enhancers and barriers to scale up, evidence in the real world for effectiveness, and capacity building. This paradigm shift is needed to conduct organizational and system-level research to evaluate the ultimate effectiveness and cost-effectiveness of interventions as implemented by real-world service providers. The panel also recommended a community-driven research agenda at the CDC that takes advantage of CDC’s unique relationships with CBOs and health departments and encourages input in the identification of potentially effective “home-grown” interventions.

7. To what extent does the behavioral research portfolio advance the current state of science?

- The panel stated that DHAP has a measurable impact among emergency rooms and health departments, but the link between science and activities implemented is not clearly stated, and priorities are not specified.
- The panel stated that DHAP’s research focuses on HIV-testing strategies and behavioral interventions, which does not appear guided by research findings. Therefore, linkages between research and program and how research findings impact incidence and prevalence are not apparent.
- The panel discussed the impact of conducting population-based research. They stated that focusing on populations resulted in research being directed at populations regardless of epidemiological burden. The panel emphasized that research should be based on the science and not other considerations. Research based on behaviors would be more realistic and would be easier to disseminate as it is what the practitioners are seeking.
- The panel stated DHAP should consider the literature about what is happening globally to guide the creation of models for the United States.
- The panel recommended the use of social marketing theory in addition to the use of traditional behavior change theory when developing programs and interventions.

8. To what extent is the research translation model effective and efficient in moving proven interventions and strategies into practice?

- The panel recommended that a social-marketing approach should be integrated into more behavioral research activities. The use of this approach in developing public communication programs is commendable, but researchers need to shift focus from individual-level behaviors to more social and structures issues (e.g., from testing to stigmas, access to service). They also recommended that health departments and CBOs be linked into campaign and program development early on to assure that local roll-outs and implementation capacities are most effectively and efficiently deployed. Social marketing
also has a central role to play in scaling up intervention dissemination and translation of research to practice.

- The panel stated that the findings of research can be disseminated faster.

9. **What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the behavioral research portfolio?**

- The panel recommended that CDC should engage in behavioral and social research—formative (Phase 1) and operations/effectiveness (Phase 4)—that target practices and behaviors that fuel HIV epidemics across populations and settings; and CDC should work with CBOs and health departments to determine how best to focus and tailor these responses in the particular communities. (For example, at the individual level—research on programs and interventions that address concurrent sexual partnerships, unprotected anal intercourse, non-disclosure of HIV status. At the societal level—research on CBO and health department capacity to deliver HIV prevention services [including, but not limited to EBIs]; scale-up of access to and uptake of male and female condoms, etc.)
- The panel recommended that DHAP review data on epidemiology and varying levels of risk at the individual level and racial and ethnic disparities to develop and implement program approaches, interventions, and public health strategies.
- The panel recommended the use of more extensive applied research methodologies to analyze the implementation of interventions in real-world conditions and the actual cost of program implementation.
- The panel recommended that research be expanded to include mass communication (especially agenda setting) and sociological theories and models (scaling social innovations, diffusion of innovations) to better capture both the complexities of the challenges and also illuminate new solutions and innovative approaches to craft them.

E. **PREVENTION PROGRAMS, CAPACITY BUILDING, AND PROGRAM EVALUATION**

The Program Panel reviewed information on HIV-prevention programs funded at the national, state, local, and community-based levels, including primary prevention, behavioral interventions (DEBIs), public health strategies, capacity-building activities and public information campaigns. The Panel was able to review the types of programs and activities being implemented, monitoring and evaluation data currently available, and plans for enhancing the prevention programs in the future.

**Topics to be addressed:**

- Community planning
- Counseling and testing
- HIV Screening
- Partner services
- Prevention interventions (behavioral, structural, biomedical)
- Communications and social marketing
- Capacity building
1. To what extent are the Division’s prevention programs, capacity-building activities, and program monitoring and evaluation approaches evidence-based, of high scientific quality, and consistent with the current state of HIV prevention science?

- DHAP lacks a mechanism for programs to explicitly interface with science and integrate various sources of data (e.g., surveillance, research agenda, evaluation) to ensure bilateral priority setting and exchange.
- DHAP should strongly promote evidence-based approaches that work, including syringe-access interventions, the safe disposal of syringes, comprehensive sex education, and condom availability and effectiveness.
- We do not know whether the national collection of HIV intervention are “working,” addressing populations at greatest risk or reducing health disparities, because evaluation data are not yet available.
- The Program Evaluation Monitoring System (PEMS) used now does not meet our needs. We are stuck with legacy elements of PEMS (i.e., the information technology infrastructure and the inability to accept and analyze data and to generate reports).
- The panel recommends that PEMS be replaced. Until a new data system is implemented, CDC needs to continue to work with state and local partners on collecting data through PEMS.
- The committee acknowledges the strengths of DEBIs in the prevention portfolio; however, DEBIs are not in and of themselves the sum total of an effective, comprehensive prevention portfolio. There are shortcomings that need to be addressed.
  - There needs to be an increase in DEBIs targeted to gay men and gay men of color, so as to limit adaptation and translation. There needs to be a synthesis of core concepts of similar DEBIs.
  - There needs to be increased attention to and resources for the use of novel technologies for prevention interventions, especially technologies used by gay and bisexual men to meet partners.
  - CDC should continue to focus on the effectiveness and cost effectiveness of its programs.
  - CDC needs to balance the limited population reach of DEBIs with the need to scale up to reach larger populations. To the extent possible, CDC should link broad-scale activities with greater reach to more specialized behavioral interventions for higher-risk individuals.
  - CDC should continue to support the evaluation of “locally grown” interventions through expertise and resources.
- The prevention communication group should review and apply the science of strategic message framing and risk communication.
- CDC should be concerned about the effectiveness and cost effectiveness of their programs.
- CDC should provide tools and technical assistance to allow for health departments to calculate their incidence estimates using the back-calculation methodology and to implement behavioral surveillance.
2. To what extent are the objectives of the Division’s prevention program, capacity building, and program monitoring and evaluation portfolios adequately described, clearly linked to, and consistent with the Division mission, goals, and priorities?

- They are not described. CDC needs to communicate its frameworks and priorities more succinctly. We need a more comprehensive presentation of DHAP’s portfolio.
- There needs to be a mapping and modeling of interventions, programs, and resources to more clearly describe how the portfolio will meet the goals. Without such mapping and modeling, the determination of the mission appropriateness and linkage (goals, etc.) cannot be accomplished.
- DHAP and NCHHSTP should revisit their mission and goals, particularly in the context of the social determinants of health discussion. There needs to be more specificity, targeting and prioritization of activities to address these overarching risk determinants.

3. To what extent do the Division’s prevention program, capacity-building, and program monitoring and evaluation activities meet the needs of CDC’s constituencies (e.g., training and technical assistance activities sufficiently address growing and evolving needs of public health workforce; program monitoring and evaluation activities result in sufficient accountability, least burden to constituents, and best utilization of data to inform programmatic efforts)?

- The panel defined constituencies as CBOs, national organizations, health departments, policy makers, communities, any grantee, and the general public (re: testing as well as social marketing).
- Evaluation data needs of local areas are not being met. CDC should start with needs assessment at the local level then go up rather than in the opposite direction. (See evaluation comments throughout). To the extent possible, CDC should move beyond process monitoring (aka PEMS) to increase program capacity for quality assurance and outcome monitoring.
- The panel recommended an increase in cultural competency of capacity building and technical assistance by implementing technical assistance programming more flexibly. Currently there is a need for more culturally matched and locally appropriate technical assistance providers.
- The panel recommended giving CDC funded organizations the opportunity to select from identified providers of capacity building and technical assistance or allow these providers to identify their own providers of technical assistance. To implement this now, CDC should allow CBA providers to use their grant resources to purchase the needed services from organizations that can provide needed and culturally competent services (if CBA providers cannot do so).
- Regarding the public health workforce, the panel recommended increasing the focus of the capacity-building program on workforce retention, public health core competencies, and capacity. These efforts should include all levels of the public health workforce (community based, health departments, and CDC).
CDC should ensure through recommendations and funding that research institutions funded by CDC collaborate and disseminate information and findings with health departments and community-based organizations.

4. To what extent are the Division’s prevention program, capacity-building, and program monitoring and evaluation activities adequately evaluated, and to what extent are the interventions and tools within the capacity-building portfolio effectively disseminated?

- While the panel recognizes the importance of this question, it could not respond to this question due to lack of data.
- DHAP should initiate a comprehensive, ongoing, and proactive review and evaluation of the portfolio and dissemination.
- DHAP needs to strengthen mechanisms to share lessons learned from evaluation activities and successful practices.

5. To what extent does DHAP have adequate capacity and sufficient resources devoted to prevention programs, capacity building, and program monitoring and evaluation, consistent with the Division mission, goals, and priorities?

- The panel concurs with CDC’s professional judgment and its budget request to Congress; however, we cannot be entirely sure whether this budget will assure the capacity to meet DHAP’s goals.
- CDC should maintain the programmatic priorities irrespective of budget increase and align the budget with these priorities.
- The panel recommends an increase in full-time equivalents (FTEs) and funding for programs and evaluation. (See other evaluation comments throughout the report).
- There should be a dedicated proportion of resources reserved for core functions such as evaluation. CDC should review other agency models for examples.
- The panel acknowledges the need to halt some activities throughout DHAP, such as legacy projects that are no longer appropriate.
- CDC should redirect discretionary resources (FTEs and funding) and scientific capacity toward the prevention programs.

6. To what extent is the mix and balance of prevention program, capacity building, and program monitoring and evaluation activities appropriate and relevant to the current epidemic?

- There is a need for a combination of effective approaches in the fight against HIV. DHAP should develop a comprehensive prevention portfolio, and it should include structural interventions reflecting a social-determinants-of-health framework and biomedical interventions.
- The intervention mix does not adequately meet the needs of gay and bisexual men of all race/ethnicities or all MSM.
- Surveillance/Data Collection does not currently represent the epidemic with the current surveillance variables (e.g. MSM versus gay-identified men; non U.S. born individuals).
• The panel recommends updating the social marketing portfolio to represent the epidemic, the state of program science, and the needs of populations. Not all social marketing materials should be translated, but many should be developed in native languages.
• Establish a well-defined, well-described portfolio and associate with it an evaluation framework and data sources that help monitor implementation and measure effectiveness.

7. **To what extent are the current nine essential components of comprehensive state and local HIV prevention programs still appropriate, based upon current surveillance, research, laboratory, epidemiological, and program evaluation data?**

• The panel recommended a redefinition of what are the essential elements of a Comprehensive HIV Prevention Program, which are defined in the Supplemental Guidance for HIV Prevention Community Planning, to incorporate activities currently carried out by non-governmental organizations at the national and community-based level.

8. **To what extent does HIV prevention community planning effectively inform programmatic efforts and meet the needs of constituents, affected populations and other partners?**

• The panel recognized the importance of community planning and its ability to increase accountability, transparency, community participation, community leadership capacity, and policy capacity.
• The panel also acknowledged the high and disproportionate level of resources allocated to community planning in many jurisdictions and the need to balance the valued process with the need for local flexibility and appropriate resource allocation to these functions.
• CDC should explore new, flexible, and more resource-efficient models for maintaining community input, accountability, and transparency. The guidance should allow for a variety of models that assure these elements (input, accountability and transparency).
• CDC needs to use the HIV Prevention Leadership Summit (HPLS) as a means of reinvigorating the energy around community planning, providing the opportunity for information and innovation transfer among jurisdictions, and developing community planning leadership. CDC should also explore regional meeting opportunities.

9. **To what extent do the Division’s HIV prevention programs address the goals of reducing health disparities; supporting program collaboration; and facilitating integration of HIV, STD, viral hepatitis, and TB services at the client level?**

• Establish a prioritized effort to examine the impact of discrimination on health outcomes. (For example, there is a need to recognize the centrality of gay and bisexual men in the HIV epidemic who face tremendous health inequalities. There is a need for a lesbian, gay, bisexual, and transgender [LGBT] focus and an office to examine the general health of LGBT people; particularly if we move toward a social-determinants-of-health model and take seriously the impact of homophobia and gender bias, among other factors, on health outcomes.)
• The panel supports the prioritization of focus on blacks, African Americans, Latinos, Asian and Pacific Islander communities, Native Americans and immigrant populations who face tremendous health disparities.
• Regarding Program Collaboration/Integration, the panel recommends increasing collaboration/interface between surveillance, evaluation, and prevention programs to ensure bidirectional learning and planning.
• The panel recommends an increase in cross-Center and collaboration between health departments and HHS Program Collaboration and Service Integration (PCSI) and consistent promotion of collaboration among programs who receive funding from multiple federal sources (CDC, HRSA, NIH, etc.)
• The panel recommends increased flexibility in cooperative agreements (e.g. 10 percent flexibility of use allowance across CDC Cooperative Agreements) to allow program and service integration in order to meet the needs of the local epidemics (e.g. HIV, TB, STD, viral Hepatitis).
• The panel recommends increased resources for intra-agency support and collaboration, more FTEs across the board, but if the programs collaborated better, then maybe they could tap into each other’s resources. And surveillance should be part of the process as well.
• There is an opportunity for coordination/collaboration across CDC programs in the Center to collaborate on social determinants of health. As HIV moves toward biomedical interventions, the panel expressed hope that we can learn from successes and failures of the other disease areas (STDs, hepatitis, etc.)
• DHAP should look for opportunities to integrate HIV into the context of other programs (school health, social services, substance abuse services job corps, etc). CDC should develop a common language and public health framework across programs.

10. To what extent are effective mechanisms in place to ensure that programmatic needs and perspectives are informing the Division’s surveillance and research agenda?

• Mechanisms are not in place (or if they are, they are not adequate). CDC needs to assure program-science interface for the setting of the scientific agenda and to assure translation of science into interventions.
• CDC should establish a practice/program community review of the research portfolio on an ongoing basis. The review should examine research priorities and portfolio.
• CDC needs to increase operational, translational, and optimization research to define the optimal mix of prevention programs.
• See above comments for program collaboration and need for mechanism to assure bidirectional exchange between research and programs.

11. What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the prevention program, capacity building, and program monitoring and evaluation portfolios?

a) Move toward social determinants of health framework.
• Social determinants of health should at least include: poverty, racism, homophobia, incarceration (and mass imprisonment), homelessness, substance abuse, immigration, and power inequities.
• This broadened approach should extend throughout the DHAP portfolio and should become part of CDC’s conversation in the national health reform discussion.
• CDC should seek additional consultation about moving toward this framework.

b) Recognize the centrality of gay and bisexual men in the HIV epidemic.

• Given that the majority of cases of HIV remain among gay and bisexual men of all races and ethnicities, DHAP should refocus and emphasize gay, bisexual, MSM, and transgender people of all race and ethnicities facing tremendous health inequities in communications, research, and programs.
• DHAP should determine if the disparities framework will be expanded to include MSM or if a complementary inequities framework is more appropriate to facilitate goal setting and use of resources.
• DHAP should prioritize gay men and differentiate between gay men and the broader category of MSM.

c) Strategically allocate DHAP resources, and improve DHAP’s organization and functioning in order to respond to the epidemic, establish broad partnerships, and innovate.

• Given the changes afoot including health reform and the development of a national AIDS strategy, DHAP should help to create a framework for resource distribution, which reflects the epidemic, recognizing the need for base funding for performing core functions. DHAP should utilize the range of data for assessing the need and capacity.
• CDC should identify more useful ways to learn from information about what is happening in the epidemic (interventions, epidemiology, etc.) at national and local levels.
• CDC should streamline external and internal clearance and procurement processes to reduce barriers to prevention program implementation (e.g. OMB and internal CDC processes).
• DHAP should increase organizational flexibility to implement innovation and change and consider organizational restructuring to ensure better program collaboration.
• CDC should develop integrated models that facilitate effective integration among the centers and their funded programs.

d) Design, fund and implement a more strategic evaluation approach to facilitate learning across the organization and across a network of providers, to inform prevention and capacity-building needs, and to address the information needs of external stakeholders.

• DHAP should distinguish which data should be collected locally and which nationally.
• CDC should orient evaluation toward both process and outcome.
• CDC should prioritize the establishment of a different and more flexible prevention evaluation data system.
• There must be close collaboration with state and local partners in the solution for the interim and long term.

e) Reclaim prevention science, and use it actively to inform policy and program.

• CDC must provide scientifically accurate, culturally appropriate information and tools to the public (e.g., syringe exchange, condom use, promotion, comprehensive sex education). We need to evaluate the impact of the Helms Amendment on the provision of information and programs to our partners, particularly if we are prioritizing sexual minorities.
• Because the science of syringe exchange in reducing HIV is broad and compelling, CDC should request a lifting of the ban on the use of federal funds for syringe exchange.
• CDC should assert the efficacy of correct and consistent condom use.
• CDC should fully support (in program and funding), comprehensive sex education as part of an effective HIV prevention strategy.
• Social marketing and health communications should reach specific populations at greatest risk for HIV as well as stakeholders.

f) The framework of “essential elements,” while historically focused on health department cooperative agreements, should now describe the entire CDC HIV portfolio, not just what is done with and through health departments.

• The “Nine Essential Elements” need to be revisited, updated, and expanded to include the modes of operation and spheres of influence in which HIV prevention operates.
• CDC should convene a consultation to examine the elements.
VI. APPENDICES

A. DHAP BACKGROUND

The Division of HIV/AIDS Prevention is one of four divisions in CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Organizationally, DHAP is structured in two divisions—one focused on intervention, research, and support and the other on surveillance and epidemiology. However, functionally DHAP operates as one division that includes 10 branches, making it the largest division in NCHHSTP and one of the largest in CDC.

1. Mission

**DHAP – Intervention, Research, and Support (IRS):** The mission of the Division of HIV/AIDS Prevention – Intervention, Research, and Support is to provide national leadership and support for HIV prevention research and the development, implementation, and evaluation of evidence-based HIV prevention programs serving populations affected by or at risk for HIV infection.

**DHAP – Surveillance and Epidemiology (S&E):** The mission of the Division of HIV/AIDS Prevention – Surveillance and Epidemiology is to provide national leadership and support for epidemiologic research and surveillance of the behaviors and determinants of HIV transmission and disease progression. The purpose of these activities is to guide the development, implementation, and evaluation of evidence-based HIV prevention programs serving persons affected by or at risk for HIV infection.

2. Division Goals and Priorities: The CDC HIV Prevention Strategic Plan

The primary goal of the Division is to decrease HIV incidence, focusing particularly on eliminating racial/ethnic disparities. CDC’s *HIV Prevention Strategic Plan through 2005 (2001–2005 Plan)* has served as a valuable guide for CDC action. CDC has used the 2001–2005 Plan to identify needs for new and expanded prevention programs and initiatives, establish priorities, and direct and target resources. Importantly, the 2001–2005 Plan established a vision not only for CDC, but for the nation as a whole. The plan set an overarching public health goal of decreasing the number of new HIV infections by half—providing a vision of what could be accomplished with a significantly expanded investment in HIV prevention in the United States and with the full implementation of the activities outlined. The 2001–2005 Plan was never fully implemented and progress did not accelerate at the desired rate through 2005; however, CDC remains committed to the aspirational goal of major reductions in HIV infection. CDC will, therefore, work with a range of partners to update the 2001–2005 Plan and its overarching goals and develop a new long-range plan to guide the nation through 2015. The new plan will be based on currently available resources but will articulate what could also be achieved with additional resources.

In the interim, CDC has developed the *HIV Prevention Strategic Plan: Extended through 2010 (Extended Plan)* to guide the agency’s efforts for the next 3 years and to define a realistic, short-term goal at a time when challenges have increased and resources for prevention are not proportionate with prevention needs. Since 2001, HIV diagnoses and risk behaviors have increased among MSM, syphilis rates have increased nationally, and more people are living with HIV than ever before—many of whom are unaware of their infection—which increases the potential for continued HIV transmission. While prevention needs have actually increased, treatment advances
have unfortunately contributed to a sense of complacency about the seriousness of HIV/AIDS. An extended strategic plan to address these challenges was essential. The short-term goal and milestones in this Extended Plan were endorsed by the CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment (CHAC).

The Extended Plan maintains the focus on core prevention priorities expressed in the 2001–2005 Plan: reducing the number of new HIV infections, increasing knowledge of HIV status, and promoting linkages to care, treatment, and prevention services. In addition, new objectives were added to make urgent priorities more explicit, including preventing new HIV infections among MSM and African Americans; addressing stigma and discrimination; promoting the use of rapid HIV tests; addressing the role of acute infection in HIV transmission; and increasing routine HIV testing in medical settings.

CDC is dedicated to helping people live longer, healthier lives by preventing new HIV infections and protecting the health of those already infected. While continuing to challenge us as a nation, CDC believes the short-term goal and milestones outlined in the Extended Plan can be achieved through the implementation of refined and targeted approaches.

The short-term goal, milestones, and accompanying objectives are based on general and specific recommendations from CHAC, formerly known as the Advisory Committee for HIV and STD Prevention. The Extended Plan serves as CDC’s strategic guide for HIV prevention through 2010.

The Extended Plan includes an expanded set of objectives that make priorities more explicit and ensure that key issues are effectively addressed. Twelve new objectives have been added, 20 existing objectives have been modified, and one objective was deleted (42 objectives total, compared to 27 in the 2001–2005 Plan).

**Short-Term Goal**

Reduce the number of new HIV infections in the United States by 5 percent per year, or at least by 10 percent through 2010, focusing particularly on eliminating racial and ethnic disparities in new HIV infections.

**Short-Term Milestone 1**
By 2010, decrease by at least 10 percent the number of persons in the United States at high risk for acquiring or transmitting HIV infection by delivering targeted, sustained, and evidence-based HIV prevention interventions.

**Short-Term Milestone 2**
By 2010, through voluntary testing, increase from the current estimated 75 percent to 80 percent the proportion of HIV-infected people in the United States who know they are infected.

**Short-Term Milestone 3**
By 2010, increase from the current estimated 50 percent to 65 percent the proportion of newly diagnosed HIV-infected people in the United States who are linked to appropriate prevention, care, and treatment services.
Short-Term Milestone 4
By 2010, strengthen the capacity nationwide to monitor the epidemic and develop and implement effective HIV prevention interventions and evaluate prevention programs.

To view the Strategic Plan in its entirety, see Appendix F. HIV Prevention Strategic Plan: Extended through 2010.

3. DHAP Organizational Structure
4. **Staffing**

**FTEs**
DHAP has a total of 442 FTE positions: 18 GS-15; 91 GS-14; 162 GS-13; 61 GS-12 and below; 44 United States Public Health Service (USPHS) Commissioned Corps officers; 8 other; and 58 vacant. The most prevalent FTE job series in DHAP are public health advisor/analyst; epidemiologist; behavioral scientist; medical officer; mathematical statistician; microbiologist and biologist; medical technician; funding resource specialist; health education specialist; and health communication specialist.

**Contractors**
DHAP also employs 163 contractors using over 18 different contract agencies to obtain technical services that are essential to the Division being able to achieve its scientific and programmatic objectives.

**Other**
In addition to FTE employees and contractors, DHAP employs 43 other employees. These employees are mostly in training and post-graduate fellowship programs designed to develop the next generation of HIV prevention workers and scientists, especially those dedicated to working in communities of color.

5. **Budget**
DHAP’s entire annual budget in FY2008 was just under $653 million. These funds were used to support intramural and extramural activities for domestic HIV Prevention programs through DHAP partners.

Within the DHAP Office of the Director (OD), the Extramural Program Management Office (EPMO) provides resource management and analysis, technical assistance, and liaison services to assist the OD and branches in funding and implementing their projects and activities more efficiently. This office works closely with Division leadership, Branch leadership, the CDC Financial Management Office (FMO) and the CDC Procurement and Grants Office (PGO) to manage and allocate DHAP funds as well as ensure compliance with federal fiscal and procurement regulations.

6. **Discretionary & Non-Discretionary**
Extramural federal funds are categorized as *discretionary funds* and *non-discretionary funds*. To better understand how these funding sources play a role in programming or allocating funding for HIV prevention activities, it is important to define these terms.

The official definition for discretionary funding from the U.S. Congress is as follows: *Discretionary funding refers to spending set by annual appropriation levels made by decision of Congress. This spending is optional, and in contrast to entitlement programs for which funding is mandatory*. By the Congressional definition, *all DHAP funding is discretionary*. 

External Peer Review
Findings and Recommendations
November 1, 2009
Page 58
However, the Congressional definition is not the definition used to describe the DHAP budget breakdown. DHAP’s definition of discretionary funding is all funding that does not have a predetermined spending directive.

For DHAP, non-discretionary funding is funding that has a predetermined allocation and cannot be used for anything other than its Congressional mandate. There are a number of ways that these funds are predetermined to be spent, below are several examples:

- Congressional language directing how the funds are to be spent
- Specific earmarks in a budget appropriation
- Long-term commitment (3–5 years) to project that makes appropriate annual progress
- Long-term commitment (5+ years) to studies that contribute to longitudinal knowledge of HIV/AIDS
- Intramural salary and operating costs

The chart below depicts how DHAP’s budget is distributed between discretionary and non-discretionary funding. As shown, most of DHAP’s funds are non-discretionary.
7. **Intramural & Extramural Funding**

Within the budgeting process, two categories of funds are used to administer all activities: intramural and extramural funds.

Below is a chart that depicts how DHAP’s 2008 budget is distributed between intramural and extramural funding. As shown, most of DHAP’s funds are expended extramurally.

<table>
<thead>
<tr>
<th>FY 2008 Budget Intramural and Extramural</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intramural $65,001,548 10%</td>
</tr>
</tbody>
</table>

External Peer Review
Findings and Recommendations
November 1, 2009
Page 60
Intramural Funds are used for activities in which the primary objective is to enhance DHAP’s internal capacities and conduct research within the Division, for example, costs associated with personnel (e.g., FTEs). In addition, intramural funds are used to cover administrative overhead costs. These are costs that are spread throughout the branches and division, which are not typically aligned to strategic planning indicators. These are the funds used to support DHAP and CDC operations. The chart below shows the distribution of intramural funds.
**Extramural Funds** are used for activities in which the primary objective is to build capacity and implement activities external to CDC. This funding provides support in the administration of extramural programs comprising cooperative agreements, grants, contracts, small purchases, Interagency Agreements (IAA), and memoranda of understanding (MOU). The Division works closely with the CDC Financial Management Office (FMO) and the CDC Procurement and Grants Office (PGO) to administer these external funds and ensure compliance with federal procurement regulations. DHAP uses these funds to support external HIV prevention activities for its partners.

**Extramural Funds, by Mission Category**
The chart below shows how DHAP’s extramural budget is divided by mission categories. It is important to note that the proportion shown for program evaluation represents only the cost of special evaluation projects (e.g., outcome evaluation of interventions delivered by CBOs). It does not include funds that health departments and CBOs receive to conduct routine monitoring of their cooperative agreement programs; these funds are included in the portion shown for intervention/implementation.
B. GUIDING QUESTIONS FOR REVIEW PANELS

Steering Committee
Topics to be addressed:
• Current mix of activities across populations and mission areas
• Current resource allocation across populations and mission areas
• Translation and dissemination of research findings

Guiding questions:
1. How proportional is the current mix of DHAP’s programs and activities to the needs of its priority populations?
2. How appropriate is the current mix of activities across mission areas (i.e., surveillance, research, program, capacity building/technical assistance, and evaluation)?
3. How appropriate is DHAP’s current allocation of resources across mission areas?
4. How adequate are DHAP’s efforts at translating and disseminating research findings and incorporating new knowledge into action?
5. To what extent does DHAP have adequate capacity and sufficient resources to address its mission, goals and priorities?
6. What are the principal gaps in DHAP’s programs, overall?

Panel 1: Planning, Prioritizing, and Monitoring Panel
Topics to be addressed:
• Strategy development and planning
• Priority setting (including Resource Allocation Model)
• Results monitoring (esp. DHAP monitoring and evaluation plan)

Guiding questions:
Planning, strategy development, and priority setting
1. To what extent are DHAP’s processes for planning, strategy development, and priority setting explicit and technically valid?
2. To what extent do these processes make adequate and appropriate use of data?
3. Is there a need for DHAP to better incorporate external input into its planning, strategy development, and priority setting? If so, how?
4. What are the strengths and weaknesses of these planning, strategy development, and priority-setting processes and what are your recommendations for improving them?
5. How appropriate are the substance and scope of DHAP’s strategic priorities relative to the Division’s mission? How might this be improved?
6. How clear and focused are DHAP’s strategic priorities, and have they been articulated and communicated adequately? How might this be improved?
7. How appropriate and relevant are DHAP’s strategic priorities to the current epidemic with respect to populations and strategies? How might this be improved?
8. How well do DHAP’s strategic priorities support 1) collaboration among HIV, STD, viral hepatitis, and TB programs and 2) integration of HIV, STD, viral hepatitis, and TB prevention services at the client level?
9. How well do DHAP’s strategic priorities support reduction of health disparities?
10. What are the principal gaps in DHAP’s strategic priorities?
National Results monitoring
11. To what extent is DHAP’s national monitoring and evaluation plan explicit and technically valid?
12. To what extent are the data sources included in the plan adequate and appropriate, and what other data sources should be included?
13. How adequate and appropriate are the outcome and impact measures described in the plan in terms of their ability to assess DHAP’s programs and their public health impact?
14. What are the strengths and weaknesses of the plan and what are your recommendations for improving it?

Panel 2: Surveillance Panel

Topics to be addressed:
- HIV case surveillance
- Incidence surveillance
- Drug resistance surveillance
- Behavioral surveillance
- Clinical surveillance

Guiding questions:
1. To what extent are the surveillance methods and resulting data of high scientific quality?
2. To what extent are the objectives of each DHAP surveillance system adequately described; clearly linked to, and consistent with, the Division mission, goals, and priorities?
3. To what extent do the surveillance systems and products adequately meet the needs of CDC’s constituencies?
4. To what extent are the surveillance systems adequately evaluated and the results effectively disseminated?
5. To what extent does DHAP have adequate capacity and sufficient resources devoted to surveillance, consistent with Division mission, goals, and priorities?
6. To what extent is the mix and balance of surveillance activities relevant to the current epidemic?
7. What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the program?

Panel 3: Biomedical Interventions, Diagnostics, Laboratory, and Health Services Research Panel

Topics to be addressed:
- Biomedical interventions
- Diagnostics and testing
- Laboratory research
- Health services research (including cost-effectiveness)
- Research-to-program translation and dissemination

Guiding questions:
1. To what extent are the biomedical, laboratory, and health services research projects and resulting data of high scientific quality?
2. To what extent are the objectives of each biomedical, laboratory, and health services research project adequately described and clearly linked to and consistent with the Division mission, goals, and priorities?
3. To what extent do the biomedical, laboratory, and health services research activities adequately meet the needs of CDC’s constituencies?
4. To what extent are the biomedical, laboratory, and health services research products adequately evaluated and the results effectively disseminated?
5. To what extent does DHAP have adequate capacity and sufficient resources devoted to biomedical, laboratory, and health services research consistent with the Division’s mission, goals and priorities?
6. Are the Laboratory Branch’s diagnostics reference functions appropriate in scope, consistent with DHAP’s mission and goals, and adequately staffed?
7. Do DHAP’s biomedical, laboratory, and health services research activities reflect the appropriate mix of basic and applied research, and to what extent is the mix and balance of activities relevant to the current epidemic?
8. To what extent does the biomedical, laboratory, and health services research portfolio adequately advance the current state of science?
9. What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the biomedical, laboratory, and health services research programs?

Panel 4: Behavioral, Social, and Structural Interventions Research Panel
Topics to be addressed:
- Behavioral, social, and structural interventions
- Communications and social marketing research
- Operational research (including cost-effectiveness)
- Linkage to care, retention in care, ART adherence
- Research-to-program translation and dissemination

Guiding questions:
1. To what extent is the behavioral research portfolio of high scientific quality?
2. To what extent are the objectives of the behavioral research portfolio adequately described; clearly linked to and consistent with the Division mission, goals, and priorities?
3. To what extent do the behavioral research findings/products meet the needs of CDC’s constituencies and inform programmatic efforts?
4. To what extent are the prevention interventions and strategies within our research portfolio adequately evaluated (adequacy of research methods) and effectively disseminated?
5. To what extent does DHAP have adequate capacity and sufficient resources devoted to behavioral research, consistent with the Division mission, goals, and priorities, and consistent with the mission of our other federal partners?
6. To what extent are the strategies, and mixture and balance of these strategies, within the behavioral research portfolio appropriate and relevant to the current epidemic (with respect to various strategies or tactics, various populations or risk groups, and individual, social, structural, or other risk determinants)?
7. To what extent does the behavioral research portfolio advance the current state of science?
8. To what extent is the research translation model effective and efficient in moving proven interventions and strategies into practice?
9. What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the behavioral research portfolio?

Panel 5: Prevention Programs, Capacity Building, and Program Evaluation Panel
Topics to be addressed:
- Community planning
- Counseling and testing
- HIV Screening
- Partner services
- Prevention interventions (behavioral, structural, biomedical)
- Communications and social marketing
• Capacity building
• Program evaluation

Guiding questions:
1. To what extent are the Division’s prevention programs, capacity building activities, and program monitoring and evaluation approaches evidence-based, of high scientific quality, and consistent with the current state of HIV prevention science?
2. To what extent are the objectives of the Division’s prevention program, capacity building, and program monitoring and evaluation portfolios adequately described, clearly linked to, and consistent with the Division mission, goals, and priorities?
3. To what extent do the Division’s prevention program, capacity building, and program monitoring and evaluation activities meet the needs of CDC’s constituencies (e.g., training and technical assistance activities sufficiently address growing and evolving needs of public health workforce; program monitoring and evaluation activities result in sufficient accountability, least burden to constituents, and best utilization of data to inform programmatic efforts)?
4. To what extent are the Division’s prevention program, capacity building, and program monitoring and evaluation activities adequately evaluated, and to what extent are the interventions and tools within the capacity building portfolio effectively disseminated?
5. To what extent does DHAP have adequate capacity and sufficient resources devoted to prevention programs, capacity building, and program monitoring and evaluation, consistent with the Division mission, goals, and priorities?
6. To what extent is the mix and balance of prevention program, capacity building, and program monitoring and evaluation activities appropriate and relevant to the current epidemic?
7. To what extent are the current nine essential components of comprehensive state and local HIV prevention programs still appropriate, based upon current surveillance, research, laboratory, epidemiological, and program evaluation data?
8. To what extent does HIV prevention community planning effectively inform programmatic efforts and meet the needs of constituents, affected populations and other partners?
9. To what extent do the Division’s HIV prevention programs address the goals of reducing health disparities; supporting program collaboration; and facilitating integration of HIV, STD, viral hepatitis, and TB services at the client level?
10. To what extent are effective mechanisms in place to ensure that programmatic needs and perspectives are informing the Division’s surveillance and research agenda?
11. What are your recommendations for changes (e.g., enhancements, additions, activities that can be de-emphasized), future directions, and priorities for the prevention program, capacity building, and program monitoring and evaluation portfolios?
C. EXTERNAL PEER REVIEW PANEL MEMBERS

External Peer Review
Chairs

Edward Hook, III
Professor of Medicine, Epidemiology, and Microbiology
University of Alabama at Birmingham Medicine
Infectious Diseases
703 19th Street South, ZRB 242
Birmingham, AL 35294-0007
Phone: 205-934-4204
Fax: 205-975-7764
E-mail: ehook@uab.edu

Jesse Milan, Jr.
Vice-President and Director
Community Health Systems
Altarum Institute
1200 18th Street, NW, Suite 700
Washington, DC 20036
Phone: 202-828-5100
Fax: 202-728-9469
E-mail: jesse.milan@altarum.org
Planning, Prioritizing, and Monitoring Panel

Co-Chairs

David Holtgrave
Professor and Chair
Johns Hopkins Bloomberg School of Public Health
Department of Health, Behavior and Society
624 N Broadway, Suite 280
Baltimore, MD 21205
Phone: 410-502-4076
Fax: 410-502-4080
E-mail: dholtgrave@jhsph.edu

Julie Scofield
Executive Director
National Alliance of State and Territorial AIDS Directors
444 North Capitol Street, NW, Suite 339
Washington, DC 20001
Phone: 202-434-8090
Fax: 202-434-8092
E-mail: jscofield@nastad.org

Panel Members

Maria Courogen
Senior Epidemiologist
Washington State Department of Health
Infectious Disease and Reproductive Health Assessment
Community and Family Health
P.O. Box 47838
Olympia, WA 98504
Phone: 360-236-3458
E-mail: maria.courogen@doh.wa.gov

George Grob
President
Center for Public Program Evaluation
38386 Millstone Drive
Purcellville, VA 20132
Phone: 540-454-2888
Fax: 540-882-4876
E-mail: GeorgeFGrob@CS.com

Amy Justice
Associate Professor of Medicine & Public Health
Yale University School of Medicine
Internal Medicine
VA Connecticut Healthcare System
950 Campbell Avenue
West Haven, CT 06516
Phone: 203-932-5711
Fax: 203-937-4926
E-mail: amy.justice2@va.gov

Ernest Hopkins
Director of Federal Affairs
San Francisco AIDS Foundation
Public Policy
5501 16th Street, NW
Washington, DC 20011
Phone: 202-726-2352
Fax: 202-726-6952
E-mail: ehopkins@sfaf.org

Jenn Kates
Vice President and Director, HIV Policy
Kaiser Family Foundation
1330 G Street, NW
Washington, DC 20005
Phone: 202-654-1423
E-mail: jkates@kff.org

Paul Kawata
Executive Director
National Minority AIDS Council
1931 13th Street, NW
Washington, DC 20009
Phone: 202-483-6622
Fax: 202-483-1135
E-mail: pkawata@nmac.org
Robin Miller  
Associate Professor  
Michigan State University  
Psychology  
Ecological Community Psychology  
Psychology Building  
East Lansing, MI 48824  
Phone: 517-432-3267  
E-mail: mill1493@msu.edu

David Ernesto Munar  
Vice President for Policy and Communications  
AIDS Foundation of Chicago  
411 South Wells Street, Suite 300  
Chicago, IL 60607  
Phone: 312-334-0933  
Fax: 312-922-2916  
E-mail: dmunar@aidschicago.org

Israel Nieves-Rivera  
Director, Policy Unit  
City and County of San Francisco  
Department of Public Health  
HIV Prevention Section  
Community Programs  
25 Van Ness Avenue  
San Francisco, CA 94102  
Phone: 415-554-9551  
Fax: 415-431-7154  
E-mail: Israel.Nieves@sfdph.org

Ron Rowell  
Program Officer - Social Justice  
The San Francisco Foundation  
Social Justice Program  
Program Department  
225 Bush Street, Suite 500  
San Francisco, CA 94104-4224  
E-mail: rmrowell@gmail.com

Carl Schmid  
Director of Federal Affairs  
The AIDS Institute  
1602B Belmont Street  
Washington, DC 20009  
Phone: 202-462-3042  
Fax: 202-328-0467  
E-mail: cschmid@theaidsinstitute.org

Ron Stall  
Professor and Chair  
University of Pittsburgh  
Department of Behavioral and Community Health Sciences  
Graduate School of Public Health  
208 Parran Hall  
130 DeSoto Street  
Pittsburgh, PA 15232  
Phone: 412-624-7933  
E-mail: rstall@pitt.edu

Monica Sweeney  
Assistant Commissioner  
New York City Department of Health & Mental Hygiene  
Bureau of HIV/AIDS Prevention and Control  
40 Worth Street  
CN A-1  
New York, NY 10013  
Phone: 212-788-3686  
Fax: 212-788-2273  
E-mail: msweeney@health.nyc.gov

Edward Tepporn  
HIV Program Director  
Asian & Pacific Islander American Health Forum  
450 Sutter Street, Suite 600  
San Francisco, CA 94108  
Phone: 415-568-3309  
E-mail: etepporn@apiahf.org

**CDC Liaisons**

**Chris Cagle**  
Associate Director for Policy and Planning CDC DHAP

**Samuel (Sam) W. Dooley**
Associate Director for Science and Program Integration
CDC DHAP

**CDC Attendees**
Richard J. (Rich) Wolitski
Jonathan H. Mermin
Stephanie Sansom
Dale Stratford
Surveillance Panel

Co-Chairs

Douglas Frye
Director, HIV Epidemiology Program
Los Angeles County Dept of Public Health
Communicable Disease Control & Prevention
600 South Commonwealth Avenue, Suite 1920
Los Angeles, CA 90005
Phone: 213-351-8190
E-mail: dfrye@ph.lacounty.gov

Amy Zapata
Surveillance Program Manager
Louisiana Office of Public Health
HIV/AIDS Program
1010 Common Street, Suite 1100
New Orleans, LA 70112
Phone: 504-568-7523
E-mail: amy.zapata@la.gov

Panel Members

Wayne Duffus
Medical Director
South Carolina Department of Health
STD/HIV Division
1751 Calhoun Street
Columbia, SC 29201
Phone: 803-898-0691
Fax: 803-898-2124
E-mail: duffuswa@dhec.sc.gov

Sandra Miranda-De León
Puerto Rico HIV/AIDS Surveillance Director
Puerto Rico Department of Health
Epidemiology Division
Fairview
Calle 17 G 42
San Juan, PR 00926
Phone: 787-763-0240
Fax: 787-763-0399
E-mail: smirandapr@gmail.com

James Hadler
Public Health Consultant
172 East Rock Road
New Haven, CT 06511
Phone: 203-772-1746
E-mail: hadler-epi@att.net

Eve Mokotoff
HIV Epidemiology Manager
Michigan Department of Community Health
1151 Taylor, Room 210B
Detroit, MI 48202
Phone: 313-876-4769
Fax: 313-876-0888
E-mail: mokotoffe@michigan.gov

Randy Mayer
Chief, Bureau of HIV, STD, and Hepatitis
Iowa Department of Public Health
321 East 12th Street
Des Moines, IA 50319-0075
Phone: 515-242-5150
Fax: 515-281-4570
E-mail: rmayer@idph.state.ia.us
Susanna Ogunnaike-Cooke  
Manager, HIV/AIDS Epidemiology Section  
Public Health Agency of Canada  
Surveillance and Risk Assessment Division  
100 Promenade Eglantine Drive  
2nd Floor, Room 2304, Building 6  
Ottawa K1A0K9, ON 00000  
Phone: 613-954-1320  
Fax: 613-957-2842  
E-mail: susanna_ogunnaikecooke@phac-aspc.gc.ca

Lucia Torian  
Deputy Director, HIV Epidemiology and Field Services  
New York City Department of Health  
Bureau of HIV Prevention and Control  
125 Worth Street  
CN 44  
New York, NY 10013  
Phone: 212-442-3461  
Fax: 212-442-3482  
E-mail: ltorian@health.nyc.gov

Sandy Schwarcz  
Section Director  
HIV/AIDS Statistics, Epidemiology, and Research Intervention Section  
San Francisco Department of Public Health  
25 Van Ness Avenue  
San Francisco, CA 94103  
Phone: 415-554-9134  
E-mail: sandy.schwarcz@sfdph.org

Barbara Werner  
Infectious Disease Consultant  
MA Department of Public Health  
Bureau of Infectious Disease Prevention, Response and Services  
26 Howe Street  
Wellesley, MA 02482  
Phone: 617-983-6365  
Fax: 617-983-6363  
E-mail: barbara.werner@state.ma.us

Rona Taylor  
Organizer  
National Women and AIDS Collective/Ms. Foundation  
12 Metrotech, 26th Floor  
Brooklyn, NY 11201  
Phone: 917-470-6494  
E-mail: rtaylor@ms.foundation.org

CDC Liaison  
Amy Lansky  
Acting Deputy Director for Surveillance, Epidemiology, and Lab Science

CDC Attendees  
Jeanne Bertolli  
Michael Campsmith  
Sam Costa  
Elizabeth DiNenno  
Pam Gruduah  
Irene Hall  
James D. Heffelfinger  
AD McNaghten  
Don Mixon  
Buzz Prejean  
Luke Shouse

External Peer Review  
Findings and Recommendations  
November 1, 2009  
Page 72
Carlos del Rio
Professor of Medicine, Co-Director
Emory Center for AIDS Research
Emory University School of Medicine
Infectious Diseases
69 Jesse Hill, Jr. Drive
Atlanta, GA 30303
Phone: 404-616-6779
Fax: 404-525-2957
E-mail: cdelrio@emory.edu

Ann Duerr
Associate Director, Scientific Affairs
HIV Vaccine Trials Network
Clinical Research Division
Fred Hutchinson Research Center
1100 Fairview Avenue North, LE 500
Seattle, WA 98108
Phone: 206-667-7938
Fax: 206-667-7711
E-mail: aduerr@hvtn.org

Dean Follmann
Assistant Director for Biostatistics
National Institute of Allergy and Infectious Diseases
Biostatistics Research Branch
6700A Rockledge Drive, Room 5138
Bethesda, MD 20892-7609
Phone: 301-451-5128
E-mail: dfollmann@niaid.nih.gov

William Kassler
Chief Medical Officer, New England Region
Centers for Medicare & Medicaid Services
JFK Federal Building, Room 2325
Boston, MA 02203
Phone: 617-565-1319
E-mail: William.kassler@cms.hhs.gov

Peter Leone
Associate Professor
University of North Carolina
School of Public Health
130 Mason Farm Road
CB# 7030
Chapel Hill, NC 27599
Phone: 919-966-2536
Fax: 919-966-6714
E-mail: zu.leone@gmail.com

Tom Liberti
Chief, Bureau of HIV/AIDS
Florida Department of Health
4052 Bald Cypress Way
Tallahassee, FL 32399
Phone: 850-245-4477
Fax: 850-414-0038
E-mail: Tom_Liberti@doh.state.fl.us

Robert Maupin
Associate Professor Obstetrics & Gynecology
Warren C. Plauche Professor of Maternal-Fetal Medicine
Louisiana State University Health Sciences Center
Obstetrics & Gynecology
School of Medicine
1542 Tulane Avenue
New Orleans, LA 70122
Phone: 504-568-4850
Fax: 504-568-5140
E-mail: rmaupi@lsuhsc.edu

Michael Pentella
Associate Director
University of Iowa
Hygienic Laboratory
102 Oakdale Campus
Iowa City, IA 52242
Phone: 319-335-4765
Fax: 319-335-4555
E-mail: michael-pentella@uiowa.edu
CDC Liaison
Bernard (Bernie) M. Branson
Associate Director for Laboratory Diagnostics
CDC DHAP

CDC Attendees
R. Michael Hendry
James D. Heffelfinger
Peter Kilmarx
Stephanie Sansom
Behavioral, Social, and Structural Interventions Research Panel

Co-Chairs

Cynthia Gomez  
Director & Professor  
San Francisco State University  
Health Equity Institute  
1600 Holloway Avenue, EP406  
San Francisco, CA 94132  
Phone: 415-405-4350  
E-mail: drcgomez@sfsu.edu

Seth Kalichman  
Professor, Psychology  
University of Connecticut  
406 Babbbidge Road  
Storrs, CT 06269  
Phone: 860-208-3706  
Fax: 860-486-8706  
E-mail: seth.k@uconn.edu

Panel Members

Judith Auerbach  
Vice President, Science & Public Policy  
San Francisco AIDS Foundation  
995 Market Street, Suite 200  
San Francisco, CA 94103  
Phone: 415-487-3080  
Fax: 415-487-3099  
E-mail: jauerbach@sfaf.org

Kyung-Hee Choi  
Professor  
University of California, San Francisco  
Center for AIDS Prevention Studies  
50 Beale Street, Suite 1300  
San Francisco, CA 94105  
Phone: 415-597-9281  
E-mail: kyung-hee.choi@ucsf.edu

Nabila El-Bassel  
Professor of Social Work  
Columbia University School of Social Work  
1255 Amsterdam Avenue, Office 814  
New York, NY 10027  
Phone: 212-851-2391  
E-mail: ne5@columbia.edu

M. Isabel Fernández  
Professor, Department of Public Health and Preventive Medicine  
Nova Southeastern University  
College of Osteopathic Medicine  
Health Professions Division  
3200 South University Drive  
Fort Lauderdale, FL 33328  
Phone: 954-262-1598  
Fax: 954-262-3714  
E-mail: mariafer@nova.edu

R. Craig Lefebvre  
Research Professor  
George Washington University  
School of Public Health and Health Services  
Prevention and Community Health  
Public Health Communication and Marketing  
2175 K Street, NW, Suite 700  
Washington, DC 20037  
Phone: 240-372-9311  
Fax: 202-994-3601  
E-mail: rcraig.lefebvre@gmail.com
Lisa Metsch  
Associate Professor  
University of Miami Miller School of Medicine  
Epidemiology  
1120 NW 14th Street, Room 917  
Miami, FL 33136  
Phone: 305-243-3470  
Fax: 305-243-6436  
E-mail: lmetsch@med.miami.edu

Steven Pinkerton  
Professor of Psychiatry & Behavioral Medicine  
Medical College of Wisconsin  
Department of Psychiatry & Behavioral Medicine  
2071 North Summit Avenue  
Milwaukee, WI 53202  
Phone: 414-955-7762  
E-mail: pinkerton@mcw.edu

Andre Rawls  
Division Director  
South Carolina Department of Health and Environmental Control  
STD/HIV/AIDS  
1751 Calhoun Street  
Columbia, SC 29201  
Phone: 803-898-0625  
Fax: 803-898-0573  
E-mail: rawlsaw@dhec.sc.gov

Kathleen Sikkema  
Professor  
Duke University  
Psychology and Neuroscience  
9 Flowers Drive  
Box 90086  
Durham, NC 27708  
Phone: 919-684-9073  
E-mail: kathleen.sikkema@duke.edu

Abraham Wandersman  
Professor  
University of South Carolina  
Psychology  
1512 Pendleton Street, Psychology USC  
Columbia, SC 29206  
Phone: 803-777-7671  
Fax: 803-777-9558  
E-mail: wandersman@sc.edu

Darrell Wheeler  
Associate Dean for Research and Community Partnerships  
Hunter College School of Social Work  
129 East 79th Street  
New York, NY 10075  
Phone: 212-452-7127  
E-mail: dwheeler@hunter.cuny.edu

CDC Liaison  
Cynthia (Cindy) Lyles  
Deputy Director for Behavioral and Social Science  
CDC DHAP

CDC Attendees  
Charles Collins  
Gary S. Marks  
David Purcell  
Jo Ellen Stryker
Prevention Programs, Capacity Building, and Program Evaluation Panel

Co-Chairs

Marjorie Hill  
Chief Executive Officer  
Gay Men’s Health Crisis  
119 West 24th Street  
New York, NY 10011  
Phone: 212-367-1248  
Fax: 212-367-1020  
E-mail: Mhill@gmhc.org

Beth Meyerson  
President  
Policy Resource Group, LLC  
P.O. Box 217  
McCordsville, IN 46055  
Phone: 317-691-7515  
E-mail: bmeyerson@policyresourcegroup.com

Panel Members

Nanette Benbow  
Director  
Chicago Department of Public Health  
Surveillance, Epidemiology and Research Section  
STD/HIV/AIDS Division  
333 South State Street, Room 2150  
Chicago, IL 60604  
Phone: 312-747-9620  
E-mail: n.benbow@gmail.com

Alma Candelas  
Director, Division of HIV Prevention  
NYS Department of Health AIDS Institute  
90 Church Street, 13th Floor  
New York, NY 10007  
Phone: 212-417-4692  
Fax: 212-417-4709  
E-mail: arc03@health.state.ny.us

Gail Bolan  
Chief, STD Control Branch  
State of California Department of Public Health STD Control Branch  
Division of Communicable Disease Control  
850 Marina Bay Parkway, Building P, 2nd Floor  
Richmond, CA 94804-6403  
Phone: 510-620-3400  
Fax: 510-620-3180  
E-mail: gail.bolan@cdph.ca.gov

Mark Colomb  
President/CEO  
My Brother's Keeper, Inc.  
P.O. Box 4682  
Jackson, MS 39296  
Phone: 601-957-3625  
Fax: 601-957-3640  
E-mail: mcolomb@mbk-inc.org
Kathryn Newcomer
Professor
George Washington University
Trachtenberg School of Public Policy and Public Administration
George Washington University
805 21st Street, NW
Washington, DC 20052
Phone: 202-994-3959
Fax: 202-994-6792
E-mail: newcomer@gwu.edu

Harry Simpson
Executive Director, CEO
Point of Change, Inc.
3028 East Grand Boulevard
Detroit, MI 48202
Phone: 313-872-2424
Fax: 313-872-5546
E-mail: harry1081@aol.com

CDC Liaison
Janet C. Cleveland
Deputy Director for Prevention Programs
CDC DHAP

CDC Attendees
Rashad Burgess
Wendy A. Harrington-Lyon
Melissa Shepherd
Dale Stratford